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Pituitary diseases are characterized by abnormalities related to undersecretion or oversecretion 
of pituitary hormones with or without local mass effects. The cause of these diseases is often 
a pituitary tumor, which is usually benign and emanates from the anterior pituitary. In general 
treatment of pituitary adenomas consists of surgery, which may be followed by radiotherapy in 
cases of a significant tumor remnant or regrowth. Due to the pituitary disease itself or after treat-
ment with surgery and/or radiotherapy, hormonal therapy may be necessary in case of hormonal 
disturbances. Literature suggests that these different treatment options may have an effect on 
cognition. However, reported results are inconsistent and mostly derived from small and het-
erogeneous (according to diagnoses and treatment) patient groups. The studies presented in this 
thesis try to unravel the effects of radiotherapy and hormonal and medical therapy on cognition 
in patients treated for pituitary diseases.
 
Pituitary function
The pituitary gland consists of an anterior (adenohypophysis) and posterior (neurohypophysis) 
lobe and produces hormones that affect different target organs (Figure 1). The adenohypophysis 
produces the following hormones:
Adrenocorticotrophic Hormone (ACTH) stimulates the adrenal cortex to induce the synthesis 
and secretion of cortisol. Cortisol is essential for life and regulates or supports a wide variety of 
important cardiovascular, metabolic, immunologic, and homeostatic functions.
Thyroid Stimulating Hormone (TSH) activates the thyroid gland in producing thyroid hor- 
mones (T3, T4) that are primarily responsible for the regulation of metabolism.
Growth hormone (GH) affects the liver in secreting Insulin-like growth factor-1 (IGF-1) which 
has growth-stimulating effects on bone, muscle and other tissue function.
Follicle stimulating hormone (FSH) and luteinizing hormone (LH) stimulate the gonadal glands 
in secreting reproductive hormones (testosterone, estrogen and progesterone) and promotes 
spermatogenesis in men and the growth and maturation of follicles in the ovaries in women.
The neurohypophysis produces the antidiuretic hormone (ADH) which regulates the amount of 






Figure 1. A selection of hormones and associated target organs produced by the pituitary.
 
Altogether, these hormones help us to live by regulating various metabolic and sexual functions 
and by allowing an adequate response to physical or emotional stress.
 
Pituitary diseases
Pituitary diseases can present with symptoms of hormonal excess or hormonal insufficiency or 
by mass effects. In the context of this thesis two conditions related to hormonal insufficiency and 




Nonfunctioning pituitary adenomas (NFAs) are clinically inactive tumors. However, they can cause 
symptoms because of increasing size and pressure on the pituitary itself or structures near the 
pituitary such as the optic nerve or optic chiasm. As a consequence neurological symptoms like 
a loss of vision or double vision, or less commonly, headache can occur. When the pituitary gland 
itself loses one or more of its functions, the syndrome will be called hypopituitarism. Symptoms 
of hypopituitarism are diverse and are related to the severity of the hormonal insufficiency and 
the function of the specific hormones. The treatment of choice of a nonfunctioning pituitary ade-
noma (NFA) is surgery which may be followed by radiotherapy in cases with tumor remnant or 
regrowth. Additional hormonal substitution is needed for those hormones that are no longer pro-
duced. Of these, glucocorticoids (hydrocortisone and cortisone acetate) are of particular interest 




There are many diseases that may cause dysfunctioning of the pituitary gland. Examples are mac- 
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roprolactinomas, cysts with pituitary localization, craniopharyngiomas, germinomas, meningeo-
mas, Ear Nose and Throat tumors, Primitive Neuroectodermal Tumors, Sheehan’s Syndrome, trau-
matic brain injury or congenital forms of hormone deficiency. All of the aforementioned diseases 
can cause secondary adrenal insufficiency.
 Patients with secondary adrenal insufficiency have impaired ACTH and thus cortisol produc-
tion and present with a slowly progressive weight and appetite loss, anorexia, and generalized 
fatigue 1. Patients with secondary adrenal insufficiency might also suffer from a reduced quality 
of life and have an increased risk of mortality and morbidity compared to normal population 2,3. 
Patients are treated with glucocorticoids (GC) to compensate for the loss of endogenous cortisol 
production. Usually this is done by oral administration of hydrocortisone or cortisone acetate 
aiming to mimic a normal circadian cortisol rhythm, with peak values in the early morning and 




Acromegaly is characterized by excess GH production. Characteristic features include large fleshy 
lips and nose, spade-like hands, frontal skull bossing, and cranial ridges. Enlarged tongue, bo-
nes, salivary glands, thyroid, heart, liver and spleen are the effects of generalized visceromegaly 4. 
Furthermore, some patients are confronted with cardiovascular complications like hypertension, 
occurring in 46% of patients with acromegaly 5. Endocrine and metabolic complications consist 
of diabetes, hypogonadism and sleep apnea. Other comorbidities may include abnormalities of 
bone and joints or colon polyps 6. The primary aim of treatment for acromegaly is to normalize GH 
and IGF-1 hypersecretion. Treatment of choice for most GH-producing pituitary adenomas is sur-
gery. However, acromegaly cannot be cured in many cases because of the inability to complete- 
ly remove the adenoma, necessitating other treatment modalities for disease control such as 
radiotherapy and antihormonal treatment.
 
Treatment for pituitary diseases
Surgery
Treatment for pituitary diseases commonly starts by surgical removal of the tumor, which can 
alleviate pressure effects and hormonal hypersecretion and may sometimes restore hormone 
hyposecretion. Transsphenoidal surgery is the most common way to remove the pituitary tumor. 
Transsphenoidal means that the tumor is approached through the sphenoidal sinus, a cavity of 
the sphenoid bone of the skull. In experienced hands, transsphenoidal surgery is associated with 
minimal morbidity and mortality 4. Less commonly, a craniotomy is indicated when the tumor is 
large and is not accessible by the transsphenoidal route. A craniotomy starts by removal of a part 
of the skull bone and involves a more extensive surgery.
 
Radiotherapy
Radiotherapy may be applied when the pituitary adenoma is not fully resected after surgery, 
because of inaccessibility for complete resection or due to critical structures in this area. Also 
in cases of tumor regrowth radiotherapy is applied. In both cases (tumor remnant or regrowth), 
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radiotherapy improves the local control rate to 95-97% for at least a period of 10 years following 
radiotherapy 7-9.
 In most pituitary patients, fractionated external beam radiotherapy is given with linear ac- 
celerators (4-18 MV). Radiotherapy for pituitary tumors varies according to fraction dose, total dose, 
irradiated volume and radiotherapy technique.  Conventional external beam radiotherapy con-
sists of two opposed lateral technique, a three-, four-, or five-field technique or a combination 
of these techniques. These techniques can be coplanar or non-coplanar. Coplanar means that 
radiation fields overlap in the same plane. Since the availability of three-dimensional radiation 
treatment planning systems in the 1990s, non-coplanar radiation techniques became possible. 
Non-coplanar means that radiation fields do not overlap in the same plane and therefore an over-
dose to normal tissue can be minimized.
 The safety of irradiation has been questioned because of concerns related to second tumor 
formation, cerebrovascular disease and increased mortality 10. Besides physical side effects, radio-
therapy for pituitary tumors may also be associated with cognitive impairments 11.
 
Hormonal and medical therapy
Hormonal therapy can be used to treat hypo- and hyperpituitarism. Hypopituitarism reflects a de-
creased secretion of one or more hormones and is a main symptom in patients with a NFA. Most 
pituitary hormones can be replaced directly or indirectly by administering the products produced 
by the target organs, e.g. hydrocortisone or cortisone acetate (cortisol) for adrenal insufficiency; 
levothyroxine for hypothyroidism; synthetic GH in case of GH deficiency; sex hormones in case of 
LH or FSH deficiencies (testosterone for male hypogonadism, estradiol for female hypogonadism) 
and desmopressin in case of ADH deficiency.
 Hyperpituitarism occurs when the pituitary adenoma produces an excess of one of the hor-
mones. Examples are an ACTH producing adenoma causing Cushing’s disease or a GH producing 
adenoma causing acromegaly. In case of GH excess after surgery and/or radiotherapy, acromega-
ly patients need GH suppressive medication, such as long-acting somatostatin analogues and/or 
pegvisomant 12.
The effects of treatment for pituitary diseases on cognition
Radiotherapy and cognition
Some studies found that irradiated patients with pituitary adenomas showed more impairments 
in the domain of executive functioning (i.e. planning, cognitive flexibility, inhibition 13) compared 
with patients who received no radiotherapy 11. However, others reported that radiotherapy was 
not responsible for the cognitive impairments that were documented in pituitary patients 8; 14-16.
 These inconsistent study results may be attributed to heterogeneity of the patients that 
were included (according to pituitary pathology and treatment) and small patient samples. Fur-
thermore, a review regarding cognitive consequences of surgery and radiotherapy for pituitary 
tumors, suggested that methodological issues may account for the apparent disparate cognitive 
data that exist in this patient group and recommended that studies should concentrate on pa-
tients with a NFA whose endocrine status is stable 17.
 Other factors that might be of influence on the incidence and severity of cognitive im-
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pairments in patients with pituitary disease after radiotherapy are related to the radiotherapy 
itself, such as fraction dose, total dose and irradiated volume. However, also other disease- and 
treatment related factors (such as white matter lesions) might play a role 18-20. Detailed dosimetric 
radiotherapy studies in relation to objective measures of cognition are lacking in humans. These 
studies offer the opportunity to relate radiation exposure of prespecified brain areas to cogni-
tive performance typically associated with these brain areas. Precise radiotherapy dose-volume 
reconstructions in the brain allow the comparison of radiation exposure of radiation-sensitive 
brain areas of different radiotherapy techniques. Many imaging studies that described the effects 
of radiotherapy on cognition focused on patients without fixed tumor localization 21-24. It would 
be better to study brain abnormalities on imaging in relation to cognition in patients with fixed 
tumor localization thereby excluding potential confounding influences of the localization of both 
brain tumor and subsequent targeted treatment and hence cognitive functioning. Furthermore, 
different brain regions appear to vary with regard to the susceptibility to radiotherapy 25-27.
 
Acromegaly and cognition
Changes in cognitive functioning can also be expected as a consequence of GH excess or GH de-
ficiency. The reason for this assumption is a wide distribution of binding sites for IGF-1 in the brain, 
in particular in the medial temporal lobe (the hippocampus) and the prefrontal cortex 28. Indeed, 
studies on the effects of GH and IGF-1 performed in GH deficient patients demonstrated an asso-
ciation between GH and cognitive performance, where poor cognitive performance was amelio-
rated with GH treatment 29-31. In acromegaly patients, cognitive functioning is also reported to be 
impaired 32;33. However in previous studies comparisons were made with healthy controls which 
is less informative because non-specific psychological factors associated with chronic illness will 
undoubtedly influence the results 34. More informative would be a comparison with patients who 
have a NFA. These patients share many disease characteristics with acromegaly patients but do 
not have the GH excess. This type of study was performed by Tiemensma et al., who concluded 
that acromegaly patients showed no cognitive dysfunctions after long-term cure 35. The relation 
of previous GH excess with impaired cognitive functioning should be further investigated by 
comparing acromegaly patients with patients who have a NFA.
 Furthermore, in case of persistent disease after surgery with or without radiotherapy, GH sup-
pressive medication is indicated. Until now no data are available on the cognitive effects of medi-
cal treatment in acromegaly.
 
Adrenal insufficiency and cognition
Cognitive impairments have been reported in healthy individuals treated with GC. There is com-
pelling evidence of an inverted “U”-shape relation between plasma GC levels and cognitive func-
tion 36. In particular, deficits in memory 37-44 and executive functioning 45, 46 are reported in associ-
ation with higher cortisol doses in healthy volunteers. These impairments could be explained by 
the fact that memory and executive functioning rely on brain structures containing high concen-
trations of GC receptors, like the hippocampus 47 and the prefrontal cortex 48. Indeed, chronically 
elevated cortisol levels are associated with reduced hippocampal volume and impairments in 
memory 41. The prefrontal cortex is, however, not only associated with executive function, but 
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also with social cognition 49 and attention 50. To our knowledge there are no studies examining 
the effects of long-term hydrocortisone replacement on cognition in patients with secondary 
adrenal insufficiency.
 
Aims of this thesis
As outlined above considerable uncertainty exists regarding the effects of treatment for pituitary 
diseases on cognition. Reliable information is however of particular importance for clinicians and 
patients to allow an informed discussion and decision on treatment strategies. Therefore we ex-
plored the effects of 1. radiotherapy on cognition in patients with a NFA, 2. current GH suppres-
sive medical treatment on cognition in acromegaly patients and 3. hydrocortisone substitution 
on cognition in patients with secondary adrenal insufficiency due to various pituitary diseases.
 
Short outline of this thesis
Chapter 2 describes a study on cognition in a large homogeneous (according to diagnosis and 
type of surgery) sample of patients treated for NFAs. In this study cognitive performance of pa-
tients who received surgery and radiotherapy was compared to the cognitive performance of 
patients who only underwent surgery. Chapter 3 further explores the effect of radiotherapy on 
cognition by relating the radiation dose on radiosensitive brain areas to cognitive test perfor-
mance. In addition, it was determined which radiotherapy technique was superior in limiting 
dose to radiotherapy sensitive brain areas. Chapter 4 assesses and compares cognition and brain 
abnormalities on magnetic resonance imaging (MRI) in NFA patients with and without cognitive 
impairments.
 The second part of this thesis explores the effects of hormonal treatment for pituitary diseases 
on cognition. Chapter 5 describes a study on cognition in acromegaly patients with persistent 
disease (i.e. on GH suppressive mediation) compared to acromegaly patients who were in re-
mission. In addition, acromegaly patients were compared to patients with a NFA, to investigate 
the effects of previous growth hormone excess. Chapter 6 examines cognitive functioning in 
patients with adrenal insufficiency. Up to now, there are no studies available on the long term 
effects of glucocorticoids on cognition in patients with adrenal insufficiency.
 Chapter 7 presents a general discussion of the results and the conclusions of this thesis. Fur-
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Nonfunctioning pituitary macroadenoma treatment, radiotherapy and cognition
Abstract
 
Context and objective Cognitive deterioration is reported in patients with a nonfunctioning 
pituitary macroadenoma (NFA) and after pituitary radiotherapy. However, reported results are 
inconsistent and are potentially confounded by different underlying pituitary disorders. The aim 
of this study was to examine cognitive functions in patients previously treated for NFA with or 
without radiotherapy.
 
Design Verbal memory was assessed with the Dutch equivalent to the Rey Auditory Verbal 
Learning Test (15 Words Test, 15 WT). Executive functioning was examined using the Ruff Figural 
Fluency Test (RFFT). We compared our patient cohort with large reference populations represen-
tative of the Dutch population.
 
Patients Eighty-four patients (62 ± 10 years) who underwent transsphenoidal surgery 8.6 ± 6.3 
years earlier participated. Patients who underwent radiotherapy (n = 39) were compared to those 
who received surgery alone (n = 45). All patients were on stable hormonal replacement therapy.
 
Results The total patient group scored significantly below the reference sample on all 15 WT 
Z-scores (95%CI): short-term memory, -0.3 (-0.5 to -0.1); total memory, -0.8 (-1.1 to -0.5); learning 
score, -0.3 (-0.5 to -0.1); delayed memory, -0.8 (-1.1 to -0.5), all P < 0.01. The total patient group 
scored significantly below the reference sample on RFFT Z-scores (95%CI): unique designs, -0.7 
(-0.9 to -0.5) and perseverative errors, -0.5 (-0.8 to -0.2), both P < 0.001. Patients who underwent 
radiotherapy showed no significant differences on cognition when compared to those who 
received surgery alone.
 
Conclusion Patients with NFA score significantly worse on cognition compared to reference 







Nonfunctioning pituitary macroadenomas (NFAs) are clinically inactive tumors. The treatment of 
choice of NFAs is transsphenoidal surgery followed by external beam radiotherapy (RT) in cases 
with tumor remnant or regrowth, thereby improving the local control rate to 95-97% for at least 
a period of 10 years following RT 1-3.
 Although effective, the safety of irradiation has been questioned because of concerns related 
to second tumor formation, cerebrovascular disease and increased mortality 4. Besides physical 
side effects, RT of pituitary tumors has been associated with cognitive impairments. Noad et al. 
compared aspects of memory, language processing, visual-spatial abilities and executive func- 
tions (i.e. planning, cognitive flexibility, inhibition 5) between patients who received either surgery 
for pituitary tumors or a combination of surgery and RT. A comparison between patients’ perfor-
mances with reference data indicated that both outcome groups show cognitive impairments 
on visual-spatial abilities and immediate memory. However, patients in the radiotherapy group 
scored significantly worse on executive functioning compared to patients without radiotherapy 
6. Other studies found cognitive impairments in pituitary patients where RT did not seem to be 
responsible 2;7-9. Furthermore, we previously found that irradiated patients with NFA did not report 
more cognitive problems than patients with NFA following surgery alone 10. Although self-rated 
questionnaires are very helpful in clinical medicine to rapidly assess possible disturbances in cog-
nitive functioning, they are unrelated to objective cognitive performance 11-13.
 The inconsistent previous study results may be attributed to the heterogeneity of the studied 
patients (according to pituitary pathology) and small patient samples. Also, in a recent review 
regarding neurocognitive consequences of surgery and radiotherapy for pituitary tumors, it was 
suggested that methodological issues may account for the apparent disparate neurocognitive 
data that exist in this patient group and recommended that studies should concentrate on 
patients with a NFA whose endocrine status is stable 14.
 Reliable information on the possible side effects of RT is of particular importance for clinicians 
and patients to allow an informed discussion and decision on treatment strategies. Therefore, 
the aim of this study was to assess objective measures of memory and executive functioning in 
a large homogeneous (according to diagnosis and type of surgery) sample of patients with NFA. 
The second aim was to compare patients who had surgery and radiotherapy with those who only 
underwent surgery. Memory and executive functioning were examined because they have been 




In this cross-sectional study, patients were recruited for participation at the endocrine outpatient 
clinic of the University Medical Center Groningen (UMCG), a tertiary referral center for pituitary 
surgery in the Netherlands. Inclusion criteria were age ≥ 18 years, treatment for a NFA and regular 
follow-up in our endocrine outpatient clinic (i.e. at least once a year). The diagnosis of NFA was 
based on two criteria: the presence of a pituitary macroadenoma (>1 cm) on imaging and the 
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absence of overproduction of any of the pituitary hormones. Pituitary deficiencies were defined 
according to generally accepted guidelines. In short, insufficiency of the HPA axis was based 
on 8 a.m. cortisol concentration < 230 mmol/l 15 and, in case of doubt, an insulin tolerance test 
(ITT). Thyroid hormone deficiency was based on a low serum fT4 concentration (<11.0 pmol/l). 
Growth hormone deficiency was based on a low IGF-1 Z-score less than -2 SD and/or an insuf-
ficient peak GH concentration (< 10 mU/l) in response to insulin-induced hypoglycaemia or a 
peak growth hormone < 18 mU/l during an arginine-GHRH test (< 18mU/l). Insufficiency of the 
pituitary – gonadal axis was defined in men as a testosterone concentration below 10 nmol/l, 
in premenopausal women (aged < 50 years) as loss of menses and in postmenopausal women 
(aged > 50 years) as LH and FSH concentrations below 15 mU/l. Diabetes insipidus was defined as 
the incapacity to properly concentrate urine (increased urine volume with low urine osmolality) 
in the face of a high plasma osmolality (and sodium). Biochemical control of adequacy of hor- 
monal substitution treatment was judged by the physicians that were responsible for the care of 
the participating patients using fT4, IGF-1 and testosterone levels where necessary. All patients in-
cluded in the present analysis underwent transsphenoidal surgery as primary treatment, in some 
cases followed by a second surgical procedure if a large remnant, amenable to surgery, persisted. 
We report data of patients who underwent transsphenoidal surgery, because this is a standard 
initial treatment in most cases. Furthermore, patients who underwent a craniotomy more often 
had larger tumors, necessitating more aggressive treatment affecting postoperative comorbidity 
and potentially cognitive performance. To assure that acute post-treatment effects had resolved, 
patients were only included at least 6 months after surgery or radiotherapy, and their hormone 
replacement schedules had to be stable during these preceding months. Patients were not eligi-
ble for participation if they had a neurological or psychiatric condition, if they had impairments 
of vision or hearing or a restriction in hand function which was expected to interfere with test 
performance. In addition, patients were not eligible when they were recently diagnosed with a 
chronic disease or a depressive disorder (as indicated by treating physician letters) and in case 
of pregnancy or an addictive disorder. Patients were asked by telephone to participate prior to 
their regular visit at our endocrine clinic, and the study procedures were performed subsequent 
to the regular outpatient visit. Of a total 173 patients with NFA visiting our endocrine clinic, 84 
consecutive patients who received transsphenoidal surgery as primary treatment were tested 
between September 2008 and December 2009. The baseline characteristics of the entire cohort 
(n = 173) did not differ from the presented study population, confirming the representativeness 
of our study population (data not shown). Approval was given by the medical ethics review com-
mittee of the UMCG.
Radiotherapy
Fractionated external beam RT was given with linear accelerators (4-18 megavolts) between 1984 
and 2008 (n = 39). Conventional external beam RT was administered using a two-opposed lateral 
technique, a three-, four-, or five-field technique or a combination of these techniques. The daily 
radiation fraction size varied from 1.8 to 2.0 Gray (Gy); the total radiation dose ranged from 45 
to 55.8 Gy with a mean of 45.8 Gy. Average treatment time was 36 days (range 32 - 61 days). In 
the time period from 1984 to 1990, the radiation dose to the tumor was prescribed at the tumor 
encompassing isodose (n = 8). From 1991 onward, the radiation dose was prescribed at a central 
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point in the tumor according to the recommendations of the Internal Commission on Radiation 
Units and Measurements at the UMCG (n = 31).
Cognitive tests
Aspects of verbal memory were assessed with the 15 Words Test (15 WT) which is a Dutch equiv- 
alent of the Rey Auditory Verbal Learning Test 16. In this test, 15 words were presented five times. 
After each trial, patients were asked to name immediately the words they remember. This allows 
the calculation of three different scores describing immediate memory:
1. The short-term memory score is based on the number of words patients were able to name  
after the first presentation of the word list.
2. The total memory score represents the total number of words patients remembered over the 
five trials.
3. The learning score describes the difference between the number of words remembered in 
the third trial in comparison with the first trial.
Besides immediate memory, delayed memory was measured.
4. The delayed recall memory score is based on the number of words patients could recall after
a period of about 30 minutes.
 Executive functioning was assessed using the Ruff Figural Fluency Test (RFFT) 17. In this test, 
patients were presented with sheets of paper on which 35 squares were printed, each with a 
fixed pattern of five dots. The test consisted of five parts which differed with regard to the de-
signs. While the configurations of dots are the same in the first three parts of the test, two types 
of distractions are added in two of these parts. In the last two parts, the configurations of the 
dots are different and without distractions. The participant was asked to produce as many dif-
ferent designs as possible by connecting two or more dots in each square with straight lines. 
The time for each part was restricted to 1 minute so that the total test time was 5 minutes. Re-
sponses were scored with regard to the total number of unique designs generated over the five 
parts. The perseverative errors score represents the total number of repetitions of the same design 
drawn. The inter-rater variability (two independent raters) was determined by Pearson’s r and was 
0.99 for both total unique designs and persevarative errors. The error ratio is the total number of 
perseverative errors divided by the total number of unique designs. As previous research dem- 
onstrated that performances on fluency tasks may be influenced by the use of strategies 18, clus-
tering and switching strategies were also analyzed. This is referred to as qualitative analysis. Clus-
ters were defined as being of a length of at least two consecutive related designs. According to 
Tucha et al., clusters in structured figural fluency tasks such as the RFFT can be analyzed based 
on addition, subtraction and rotation strategies 18. Clusters that contained errors were counted 
when at least two valid designs were included. However, errors were not calculated with regard 
to cluster size. Mean cluster size was determined by dividing the number of unique designs within 
clusters by the number of clusters generated. Because there is the possibility that clusters overlap, 
designs could belong to several clusters simultaneously. Beside the mean cluster size, the length 
of the largest cluster was also registered. Finally, the number of switches was analyzed. A switch was 
defined as the change between two clusters that follow immediately after each other. The inter- 
rater variabilities (two independent raters) were determined by Pearson’s r and ranged from 0.85 to 
0.98. All of the aforementioned scores were calculated over the whole test period of 5 minutes.
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Questionnaires and protocol
A common questionnaire on demographic and health-related data was used with special atten-
tion for educational level, social status, full-time/part-time employment, social security benefit, 
comorbidity, use of medicine, cardiovascular risk factors, traumatic brain injury and dementia. 
Education level was determined by using a Dutch education system, comparable to the ISCED 
(International Standard Classification of Education 19). This scale ranges from 1 (elementary school 
not finished) to 7 (university level). The Hospital Anxiety and Depression Scale (HADS) consists of 
14 items and measures anxiety and depression 20. Each item is scored as a number, with a maxi-
mum score for each subscale (anxiety or depression) of 21. Higher scores indicate more severe 
anxiety or depression.
 In fixed order, the test protocol was as follows: (1) the 15 WT: direct recall, (2) the RFFT, (3) a 
common questionnaire to assess baseline information, (4) physical examination: length, weight, 
blood pressure, waist circumference, hip circumference and compliance to the test situation, 
(5) the HADS and finally (6) the 15 WT: delayed recall. The assessment took approximately forty 
minutes and was performed directly after or just before visit to the outpatient clinic. All testing 
and scoring of tests were performed by trained personnel.
Reference data: healthy control subjects
The performances of patients were compared to Dutch controls. Normative data for the HADS 
were derived from Spinhoven et al. 20. In their study, psychometric properties of the HADS were 
assessed in six different groups of Dutch subjects (n = 6165): (1) a random sample of younger 
adults (18-65 years) (n = 199); (2) a random sample of elderly subjects of 57 to 65 years of age (n 
= 1901); (3) a random sample of elderly subjects of 66 years and older (n=3293); (4) a sample of 
consecutive general practice patients (n=112); (5) a sample of consecutive general medical out-
patients with unexplained somatic symptoms (n=169); and (6) a sample of consecutive psychiat- 
ric out-patients (n=491). In all six groups, an authorized Dutch translation of the HADS was used. 
General population mean and standard deviations scores were used from 18 to 65 years and >65 
years to calculate Z-scores. Reference data for the 15 WT were derived from control subjects of the 
Maastricht Aging Study 16. In this study, 1780 healthy participants between 24 and 81 years were 
evaluated on a Dutch adaptation of the Rey Verbal Learning Test (RVLT), the 15 WT. Regressions 
models given by the authors were used to determine the exact Z-scores. The final test scores were 
controlled for age, sex, and education.
 Reference data for the RFFT were derived from a sample (n = 10,289) of the LifeLines Cohort 
Study 21. Reference groups are stratified by a matrix of 8 education levels and 13 age levels (half 
decades from 20 to 85 years). Each cluster consisted on average of 120 subjects. RFFT forms were 
analyzed by a computerized pattern recognition program. There was a good internal consistency 
(n = 373) between computerized rating and human rating for unique designs (Cronbach’s α = 
0.99) and perseverative errors (Cronbach’s α = 0.97). Using a Bland Altman analysis, a near perfect 
level of agreement was found between these two rating methods with intraclass correlation for 
unique designs: 0.99 and perseverative errors: 0.96. Using the mean and standard deviation scores 





The analyses were all carried out using the SPSS package for Windows version 16.0.2. Statistical 
analysis between patient groups was performed using t-tests. Categorical variables were ana-
lyzed by using chi-square tests. The following data are presented in tables: (1) Raw scores (Mean ± 
SD), (2) the number and percentage of patients scoring below the median (i.e. ≤ 50th percentile 
on the basis of reference data) and (3) the number and percentage of patients scoring impaired. 
According to Lezak, cognitive impairment on a test was defined as a performance equivalent 
to or below the 10th percentile of the reference samples (equivalent to a Z-score of ≤ -1.3) 22. 
For graphical representation, study population mean Z-scores with 95% confidence intervals is 
shown. Because some of the variables were not normally distributed, nonparametric tests were 
used to confirm the findings of parametric tests. The nonparametric analysis supported the re-
sults of the parametric tests; therefore, only the results of the parametric tests are reported. The 
two-tailed alpha level of < 0.05 was considered as statistically significant. In case of statistical dif-






Eighty-four patients (55 men and 29 women, aged 62 ± 10 years, range 36 to 81 years) participat- 
ed in the present study. Thirty-nine patients received transsphenoidal surgery and postoperative 
RT (RT+ group), whereas 45 patients did not receive RT (RT- group). Patients’ characteristics are 
given in Table 1. Patients who underwent RT were significantly younger at the time of surgery 
and their duration of follow-up from first surgery was longer. In addition, the irradiated patients 
used more hormonal substitution, and this reached significance for the use of adrenal and thyroid 
hormones. Average time between first surgery and radiotherapy was approximately 17 months. 
Feelings of anxiety and depression were comparable between the RT+ and RT- group and not 
indicative of clinical anxiety and depression. Social status, full-time/part-time employment, social 
security benefit and comorbidity were all comparable between both outcome groups at the time 
of assessment (data not shown).
 
Cognitive tests
The total patient group scored significantly lower on the 15 WT compared to the reference sam-
ple, Z-scores (95% confidence interval, P level ): short-term memory, -0.3 (-0.5 to -0.1, P = 0.009); 
total memory, -0.8 (-1.1 to -0.5, P < 0.001); learning score, -0.3 (-0.5 to -0.1, P = 0.006); delayed 
memory, -0.8 (-1.1 to -0.5, P < 0.001). However, there were no significant differences between the 
RT+ and RT- group (Table 2, Figure 1).
The total patient group scored significantly lower on the RFFT for the measures of unique designs 
and perseverative errors compared to the reference sample, Z-scores (95% confidence interval, 
P level): unique designs, -0.7 (-0.9 to -0.5, P < 0.001); perseverative errors, -0.5 (-0.8 to -0.2, P < 
0.001). 
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There was a trend in the error ratio, -0.3 (-0.6 to 0.01, P = 0.058). Comparisons between the RT+ 
and RT- group showed no significant differences on executive functioning for both qualitative 
and quantitative analyses (Table 2, Figure 1).
Table 1. Clinical characteristics of patients treated for nonfunctioning pituitary macroadenoma
Table 1. Clinical characteristics of patients treated for nonfunctioning pituitary macroadenoma 
  Total RT+ RT-  
N 84 39 45 P-value* 
     
Basic characteristics     
Age (y) 62 (10) 60 (11) 63 (9) 0.234 
Sex (males/females) 55/29 25/14 30/15 0.805 
Educational level     
(1/2/3/4/5/6/7) 1/8/1/18/37/16/3 1/3/1/11/18/3/2 0/5/0/7/19/13/1 0.142 
Surgery     
Age at surgery (y) 52.9 (12.4) 48.5 (12.8) 56.8 (10.8) 0.002 
Average time since surgery (y) 8.6 (6.3) 11.7 (7.0) 5.9 (4.0) <0.001 
< 1 – 5 years (number, (%)) 
5 – 10 years  











   
Patients with 2nd surgery (%) 11 15 7 0.198 
Radiotherapy     
Age at radiotherapy (y)  50 (13)   
Time between primary surgery 
and RT (y) 
 1.4 (1.5)   
Hormonal substitution     
No. of hormone replacements     
(0/1/2/3/4/5) 11/17/13/24/19/0 1/8/4/17/9/0 10/9/9/7/10/0 0.010 
Glucocorticoid (%) 64 77 53 0.023 
Thyroid hormone (%) 66 82 51 0.003 
Growth hormone (%) 31 39 24 0.116 
Sex hormone (%) 55 54 56 0.875 
Desmopressin (%)  12 13 11 0.809 
     
RT+: group of patients who underwent surgery and radiotherapy 
RT-: group of patients who underwent surgery alone  





















Table 2. Cognitive performance of patients treated for nonfunctioning pituitary macroadenoma
 
 
Table 2. Cognitive performance of patients treated for nonfunctioning pituitary macroadenoma  
  Total RT+ RT-  
N 84 39 45 P-value* 
     
15 Words Test     
Short-term memory     
Mean (SD) 4.6 (1.9) 4.4 (1.9) 4.7 (1.9) 0.467 
≤ 50th perc. (%) 67 69 64 0.643 
≤10th perc. (%) 20 26 16 0.251 
Total memory     
Mean (SD) 37.6 (11.3) 36.2 (11.6) 38.8 (10.9) 0.294 
≤ 50th perc. (%) 76 85 69 0.091 
≤10th perc. (%) 37 46 29 0.102 
Learning score     
Mean (SD) 3.2 (2.0) 3.0 (2.0) 3.3 (2.0) 0.419 
≤ 50th perc. (%) 63 72 56 0.124 
≤10th perc. (%) 19 23 16 0.381 
Delayed memory      
Mean (SD) 7.1 (3.4) 7.3 (3.5) 6.9 (3.4) 0.600 
≤ 50th perc. (%) 76 74 78 0.714 
≤10th perc. (%) 38 39 38 0.949 
Ruff Figural Fluency Test     
Unique designs     
Mean (SD) 58.5 (25.1) 55.7 (29.0) 60.9 (21.2) 0.352 
≤ 50th perc. (%) 74 74 73 0.915 
≤10th perc. (%) 37 44 31 0.237 
Perseverative errors     
Mean (SD) 9.9 (10.9) 7.8 (8.2) 11.7 (12.6) 0.098 
≤ 50th perc. (%) 80 82 78 0.627 
≤10th perc. (%) 18 21 16 0.554 
Error ratio     
Mean (SD) 0.2 (0.2) 0.2 (0.2) 0.2 (0.2) 0.411 
≤ 50th perc. (%) 76 85 69 0.091 
≤10th perc. (%) 13 15 11 0.563 
Clustering & Switching     
Mean cluster size (SD) 2.7 (0.7) 2.7 (0.7) 2.7 (0.8) 0.385 
Mean no. clusters (SD) 12.2 (6.2) 11.3 (6.7) 13.0 (5.7) 0.175 
Mean no. switches (SD) 3.9 (3.5) 3.6 (3.8) 4.1 (3.3) 0.427 
Largest Cluster (SD) 4.6 (2.0) 4.6 (2.1) 4.7 (2.1) 0.352 
RT+: group of patients who underwent surgery and radiotherapy 
RT-: group of patients who underwent surgery alone  
* RT+ versus RT-.  
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Data are mean Z-scores and 95% confidence intervals
RT+: group of patients who underwent surgery and radiotherapy
RT-: group of patients who underwent surgery alone
RFFT: Ruff Figural Fluency Test
 
Discussion
This study shows that patients treated for NFAs scored significantly worse than reference popu-
lations on both verbal memory and executive functioning. However, no significant differences 
were found between patients who received radiotherapy compared to patients who underwent 
surgery alone.
 Our finding is in agreement with most studies mentioned before, even though most of them 
used heterogeneous patient groups with different tumor types 2;6-9;23. Recently, Tiemensma et al. 
described cognitive functioning in Cushing and NFA patients 24. Although the main scope of this 
article was on irreversible effects of previous hypercortisolism, comparisons of patients with NFA 
and matched controls were made. The NFA patient group scored significantly below the matched 
control group on one memory subtest and on two tests of executive functioning. However, the 
authors do not describe whether they corrected for multiple testing. Furthermore, no significant 
  
Chapter 2
differences were found on global cognitive functioning. For this latter assessment, the Mini Men-
tal State Examination was used, which is known to be rather insensitive due to its ceiling effect 
25. The results of this study are also comparable to those of Guinan et al. who performed a large 
and detailed study 7. They found anterograde memory deficits (i.e. difficulties in learning new 
information) in all patient groups (acromegaly, Cushing’s disease, NFAs and prolactinoma) when 
compared to control subjects. There were no effects of different treatment modalities (type of 
surgery, radiotherapy or use of medication) on memory scores.
 In a study by McCord et al., distinct differences were reported compared to our results 2. They 
found significantly more severe memory problems in the RT+ group compared to the RT- group. 
However, the patient group was heterogeneous according to tumor etiology and treatment. 
Another limitation of their study might be that patients had to rate their memory problems 
themselves by filling out a questionnaire. Self-rated questionnaires must be interpreted with cau-
tion. Numerous studies that focused on the subjective experience of cognitive functioning have 
consistently found that self-reports are unrelated to objective performance in distinct patient 
groups 11-13. Noad et al. found that irradiated patients performed significantly worse than patients 
treated with surgery alone on an executive functioning test 6. The discrepancy between the study 
of Noad et al. and the results of this study might be explained by the fact that different tests 
for executive functioning were used. Executive functioning is a broad term, encompassing e.g. 
inhibition, cognitive flexibility and planning. While Noad et al. used a test that relied mainly on 
the capability of inhibition, the RFFT relies mainly on planning capacities. As different cognitive 
functions rely on different brain networks, which could be affected more or less because of radio-
therapy, future studies on the effects of radiotherapy should aim to correlate radiation field and 
dose to cognitive performance. This type of studies has not been performed in patients who re-
ceived pituitary radiotherapy. These studies will provide insight into potential radiation-induced 
brain damage and actual cognitive performance. Although we found no significant differences 
between the RT+ and the RT- group, the RT+ patients almost always scored below the RT- group. 
There is a possibility that brain-induced damage by radiotherapy is very subtle, and therefore larg- 
er patient groups are required. A retrospective power analyses revealed that at least 392 patients 
in each group would have been required to detect significant differences in both tests used with 
80% power, illustrating that the effects of RT are at most very small and unlikely to be of clinical 
relevance.
 Although we did not find significant differences between the RT+ and RT- group, the total 
group scored significantly worse compared to reference data. This can be a consequence of trans-
sphenoidal surgery. Peace et al. found that nearly one-third of patients who underwent this type 
of surgery (without radiotherapy) had memory and executive test scores below the 10th percen-
tile compared to < 5% of the controls. In addition, they found that many nonsurgical patients 
suffer from mild cognitive impairments 9. Thus, it is likely that the primary disease or hormonal 
abnormalities secondary to the tumor and/or its treatment could be responsible. Over the last 
decades, evidence has accumulated, indicating that glucocorticoïds play an important role in 
the regulation of memory 26. Moreover, research in congenital hypothyroid patients or hypothy-
roidism in adulthood has shown the importance of thyroid hormone for cognition 27;28. However, 
we found no effects on cognitive performance of glucocorticoïd or thyroid substitution therapy 
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in multivariate analysis within our study population (data not shown). Our hormonal substitution 
therapy appeared to be adequate (i.e. hormonal Z-scores in the normal range) despite its intrinsic 
imperfections. Alternatively, cognitive impairments could be a result of nonspecific psychologi-
cal factors associated with having a chronic illness. A recent systematic review found that type 2 
diabetes, hypertension and, to a lesser extent, obesity and dyslipidemia are also associated with 
mild-to-moderate decrements in cognitive functioning in nondemented persons. The profile 
of cognitive decrements was nonspecific, with most consistent results found in the domains of 
memory, processing speed and cognitive flexibility 29.
 Age at surgery is another potential risk factor that might have influenced the results. Younger 
age at surgery could be a favorable recovery factor after brain surgery. This could be because of a 
more neuroplastic brain at younger age and special (vascular) vulnerability in the elderly patients 
30. In our study, the RT+ group was younger than the RT- group at pituitary surgery and as a result 
had a longer average time since surgery. However, both age at surgery and time since surgery or 
radiotherapy were not associated with cognitive functioning (data not shown).
 In conclusion, in patients treated for nonfunctioning pituitary adenomas memory and execu-
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Pituitary radiotherapy and cognition
Abstract
 
Objective The hippocampus and prefrontal cortex (PFC) are important for memory and execu-
tive functioning and are known to be sensitive to radiotherapy (RT). Radiation dosimetry relates 
radiation exposure to specific brain areas. The effects of various pituitary RT techniques were 
studied by relating detailed dosimetry of the hippocampus and PFC to cognitive performance.
 
Methods In this cross-sectional design, 75 nonfunctioning pituitary macroadenoma (NFA) pa-
tients (61 ± 10 years) participated and were divided into irradiated (RT+, n = 30) and non-irra-
diated (RT-, n = 45) groups. The RT+ group (who all received 25 fractions of 1.8 Gray; total dose: 
45 Gray) consisted of three RT technique groups; three-field technique, n = 10; four-field tech-
nique, n=15 and five-field technique, n=5. Memory and executive functioning were assessed by 
standardized neuropsychological tests. A reconstruction of the dose distributions for the three RT 
techniques was made. The RT doses on 30, 50 and 70% of the volume of the left and right hip-
pocampus and PFC were calculated.
 
Results Cognitive test performance was not different between the four groups, despite differenc- 
es in radiation doses applied to the hippocampi and PFC. Age at RT, time since RT, and the use 
of thyroid hormone varied significantly between the groups; however, they were not related to 
cognitive performance.
 
Conclusion This study showed that there were no significant differences on cognitive perfor-
mance between the three-, four- and five-field RT groups and the non-irradiated patient group. A 
dose-response relationship could not be established, even with a radiation dose that was higher 
on most of the volume of the hippocampus and PFC in case of a four-field RT technique com-








Patients with a nonfunctioning pituitary macroadenoma (NFA) may receive postoperative radio-
therapy (RT) for local control 1;2. However, the safety of RT to the brain has been questioned be-
cause of concerns related to second tumor induction, cerebrovascular disease, and increased 
mortality 3. In addition, accelerated cognitive decline may develop over many years following 
RT. The incidence and severity of this complication is dependent on radiation fraction dose, total 
dose, and volume, but can also be influenced by other disease- and treatment-related factors 4. 
Susceptibility of different brain regions is also reported to vary 5-7. In addition, time since RT is con-
sidered to be an important factor because deterioration in cognitive functions might appear only 
after a few years 8. Furthermore, both younger and older patients carry a greater risk of cognitive 
impairment from RT 9.
 Patients who received RT for primary brain tumors performed worse on tests for executive 
functioning 10. Other groups reported poor memory performance in irradiated low-grade glioma 
patients 11. However, controversy remains because studies on the effects of RT on cognition are 
usually difficult to interpret, giving differences in tumor localization, which are likely to affect vari-
ous cognitive domains. In addition, Armstrong et al. described that radiation effects appear to be 
severe only in a minority of patients. Further, risk of cognitive impairment was found to be related 
to direct and indirect effects of cancer type, concurrent clinical factors, and premorbid risk factors 9.
 In pituitary adenoma patients, Noad et al. 12 found that patients who received postoperative 
RT performed worse on executive functioning when compared with patients who underwent 
surgery alone. However, we 13 and others 14-17 did not find an effect of RT on the cognitive perfor-
mance of patients treated for pituitary disease.
 Although older literature supports a role for RT-induced cognitive decline, it remains to be es-
tablished whether modern pituitary RT techniques result in poorer cognitive performance. How- 
ever, detailed dosimetric RT studies in relation to objective measures of cognition are lacking in 
humans. These studies offer the opportunity to relate radiation exposure of prespecified brain 
areas to cognitive performance. Precise RT dose–volume reconstructions in the brain allow the 
comparison of radiation exposure of radiation-sensitive brain areas of different RT techniques. In 
this context, the temporal lobe/hippocampus and the prefrontal cortex (PFC) appear to be espe-
cially relevant. The temporal lobe is crucial for acquisition of new information as well as its storage 
and retrieval. The hippocampus within the temporal lobe is important for declarative memory, 
i.e. the conscious recollection of facts and events 18. Specifically, the left and right hippocampus 
appear to have different memory functions 19;20. The hippocampal granule cell layer, which under-
goes neural regenesis, seems to be more sensitive to RT than glial or neural cells in the brain, as 
shown in animal models 21. The PFC is of great importance for executive functioning (i.e. planning, 
cognitive flexibility and inhibition 22) 23, which seems to decrease after RT 10;12.
 Previously, we found no major influence of pituitary RT on cognition in patients with NFA 24. 
However, smaller effects could not be excluded. Therefore, we decided to refine the strategy to 
relate the radiation dose to radiosensitive brain areas (i.e. the hippocampus and PFC) to cognitive 
test performance typically associated with these brain areas. In addition, we studied which RT 
technique was superior at limiting dose to the hippocampus and PFC.
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In this cross-sectional study, patients were recruited for participation at the endocrine outpatient 
clinic of the University Medical Center Groningen (UMCG), a tertiary referral center for pituitary 
surgery in the Netherlands. Inclusion criteria were age ≥ 18 years, treatment for NFA, and regular 
follow-up in our endocrine outpatient clinic (i.e. at least once a year). The diagnosis of NFA was 
based on two criteria: the presence of a pituitary macroadenoma (>1 cm) on magnetic resonance 
imaging (MRI) and the absence of overproduction of any of the pituitary hormones. Pituitary 
deficiencies were defined according to generally accepted guidelines. Biochemical control of 
adequacy of the hormonal substitution treatment was judged by the physicians responsible for 
the care of participating patients, with the use of free thyroxine, insulin-like growth factor 1, and 
testosterone measurements where necessary. All patients included in the present analysis under-
went transsphenoidal surgery (TSS) as a primary treatment, in some cases followed by a second 
surgical procedure if a large remnant, accessible only by surgery, persisted. We only report data 
of patients who underwent TSS because this is a standard initial treatment in most cases. Pa-
tients who underwent a craniotomy more often had larger tumors, necessitating more aggressive 
treatment, which affect postoperative comorbidity and potentially also cognitive performance. 
To assure that acute post-treatment effects had resolved, patients were included only at least 6 
months after surgery or RT. Furthermore, their hormone replacement schedules had to be stable 
during these preceding months. Patients were not eligible for participation if they had a (prior) 
neurological or psychiatric condition, if they had impairments of vision or hearing, or a restriction 
in hand function, which was expected to interfere with test performance. In addition, patients 
were not eligible when they were recently diagnosed with a chronic disease or a depressive dis-
order, indicated by letters of the attending physicians, and in case of pregnancy or an addictive 
disorder. Prior to their regular visit at our endocrine clinic, patients were approached by telephone 
to participate. Of a total of 173 NFA patients visiting our endocrine clinics, 75 consecutive patients 
who received TSS as primary treatment with or without a three-, four- or five- field RT techniques 
were tested between September 2008 and December 2009. The baseline characteristics of the 
entire cohort (n = 173) did not differ from the presented study population, confirming the re-
presentativeness of our study population (data not shown). Approval was given by the medical 













Table 1. Clinical characteristics of patients treated for nonfunctioning pituitary macroadenoma (NFA) 
with different radiotherapy (RT) techniques (three, four, and five fields) and without RT (RT-). Data are 
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Radiotherapy
Fractionated external beam RT was given with linear accelerators (4-18 megavolts) between 1987 
and 2008 (n = 30). In this time period, pituitary RT was performed using a three-, four-, or five-
fields techniques (Table 1). The three-field technique replaced the two lateral opposed field tech-
nique because the older two-field technique irradiated a large volume of normal brain with an 
equivalent or even higher dose of what was applied to the tumor, with reports of brain necrosis 
as a result of that. The three-field technique consisted of two lateral fields and one vertex field. 
Since the availability of three-dimensional (3D) radiation treatment planning systems in the 1990s 
of the previous century, non-coplanar radiation techniques became possible. With non-coplanar 
techniques, RT fields do not overlap in the same plane and therefore overdose to normal tissue 
can be minimized. The three- and five-field irradiation techniques used in this study were co-
planar, but the four-field technique was non-coplanar. This four-field technique was planned to 
spare the temporal lobes.
 For all the three multiple field RT techniques, similar dose prescriptions were used: 1.8 Gray 
(Gy) with a total dose of 45 Gy given in 25 fractions. The median overall radiation treatment time 
was 35 days (range 31- 37 days). From 1987 to 1990, the RT dose of the tumor/pituitary adenoma 
was prescribed at the tumor encompassing isodose (n = 2). From 1991 onwards, the RT dose was 
prescribed at a central point in the tumor/pituitary adenoma according to the recommendations 
of the Internal Commission on Radiation Units and Measurements (n = 28).
 The dose distribution effects of the three different RT techniques were reconstructed using 
a planning computed tomography (CT) and MRI scan of the head of a 64-year-old patient that 
served as a model for the whole patient group. The gross tumor volume (i.e. pituitary adenoma 
remnant) and brain areas at risk (i.e. the left and right hippocampus and PFC) were delineated 
on MRI with a slice thickness of 1 mm. A planning target volume was generated by adding a 3D 
margin of 10 mm around the gross tumor volume. The normal tissues at risk were delineated with 
the help of an experienced neuroradiologist (L C Meiners) according to the established neuroana-
tomical bounderies 25-27. To allow a direct comparison, the 3D conformal RT treatment plans were 
generated using the Pinnacle treatment planning system (version 8.0h). The 3D dose distribution 
of the left and right hippocampus and PFC were based on a 3D reconstruction of the CT scan. 
For a description of the RT exposure of the left and right hippocampus and the PFC, the RT dose 
received at 30, 50 and 70% of these brain area volumes are given. These percentages were chosen 
because at 30, 50 and 70%, the largest differences between the three different RT techniques in 
radiation dose were seen. These percentage points give a better idea of the dose distributions 
compared with mimimum, maximum, mean, and SDS.
 
Cognitive tests
Aspects of verbal memory were assessed with the 15 Words Test (15 WT) which is a Dutch equiv- 
alent of the Rey Auditory Verbal Learning Test 28. In this test, 15 words were presented five times. 
After each trial, patients were asked to name immediately the words they remembered. This 
allowed the calculation of three different scores describing immediate memory:
1. The short-term memory score is based on the number of words patients were able to name 
after the first presentation of the word list.
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2. The total memory score represents the total number of words patients remembered over the 
five trials.
3. The learning score describes the difference between the number of words remembered in the 
third trial in comparison with the first trial.
Besides immediate memory, delayed memory was measured.
4. The delayed memory score is based on the number of words patients could recall after a period 
of about 30 minutes.
 Executive functioning was assessed using the Ruff Figural Fluency Test (RFFT) 29. In this test, 
patients were presented with sheets of paper on which 35 squares were printed, each with a fixed 
pattern of five dots. The test consisted of five parts, which differed with regard to the designs. 
While the configurations of dots are the same in the first three parts of the test, two types of 
distractions are added in two of these parts. In the last two parts, the configurations of the dots 
are different and without distractions. The participant was asked to produce as many different 
designs as possible by connecting two or more dots in each square with straight lines. The time 
for each part was restricted to 1 minute so that the total test time was 5 minutes. Responses 
were scored with regard to the total number of unique designs generated over the five parts. The 
perseverative errors score represents the total number of repetitions of the same design drawn. 
The interrater variability (two independent raters) was determined by Pearson’s r and was 0.99 
for both total unique designs and perseverative errors. The error ratio is calculated by the total 
number of perseverative errors divided by the total number of unique designs.
 
Questionnaires and protocol
A common questionnaire on demographic and health-related data was used with special atten-
tion for educational level, social status, full-time/part-time employment, social security benefit, 
comorbidity, use of medicine, cardiovascular risk factors, traumatic brain injury, and dementia. 
Education level was determined by using a Dutch education system, comparable to the Interna-
tional Standard Classification of Education (ISCED) 30. This scale ranges from 1 (elementary school 
not finished) to 7 (university level). The Hospital Anxiety and Depression Scale (HADS) consists of 
14 items and measures anxiety and depression 31. Each item is scored as a number, with a maxi-
mum score for each subscale (anxiety or depression) of 21. Higher scores indicate more severe 
anxiety or depression.
 In fixed order, the test protocol was as follows: (1) the 15 WT: direct recall, (2) the RFFT, (3) a 
common questionnaire to assess baseline information, (4) physical examination: length, weight, 
blood pressure, waist circumference, hip circumference and compliance to the test situation, (5) 
the HADS and finally (6) the 15 WT: delayed recall. The assessment took approximately forty min-
utes and was performed directly after or just before patients’ visit to the outpatient clinic. All 
testing and scoring of tests were performed by trained personnel.
 
Reference data: healthy control subjects
The performances of patients were compared with Dutch controls. Normative data for the HADS 
were derived from Spinhoven et al. 31. In their study, psychometric properties of the HADS were 
assessed in six different groups of Dutch subjects (n = 6165): (1) a random sample of younger 
7  
Pituitary radiotherapy and cognition
adults (18-65 years) (n = 199); (2) a random sample of elderly subjects of 57 to 65 years of age (n 
= 1901); (3) a random sample of elderly subjects of 66 years and older (n = 3293); (4) a sample 
of consecutive general practice patients (n = 112); (5) a sample of consecutive general medi-
cal outpatients with unexplained somatic symptoms (n = 169); and (6) a sample of consecutive 
psychiatric outpatients (n = 491). In all six groups, an authorized Dutch translation of the HADS 
was used. General population mean and SDS were used from 18 to 65 years and > 65 years to 
calculate Z-scores.
 Reference data for the 15 WT were derived from control subjects of the Maastricht Aging Study. 
In this cohort, 1780 healthy participants between 24 and 81 years were evaluated on a Dutch 
adaptation of the Rey Verbal Learning Test, the 15 WT 28. Regression models given by the authors 
were used to determine accurate Z-scores. The final test scores were controlled for age, sex, and 
education. Reference data for the RFFT were derived from a sample (n = 10,289) of the LifeLines 
Cohort Study 32. Reference groups were stratified by a matrix of eight education levels and 13 age 
levels (half decades from 20 to 85 years). Each cluster consisted on average of 120 subjects. RFFT 
forms were analyzed by a computerized pattern recognition program. There was a good internal 
consistency (n = 373) between computerized rating and human rating for unique designs (Cron-
bach’s α = 0.99) and perseverative errors (Cronbach’s α = 0.97). Using a Bland-Altman analysis, a 
near perfect level of agreement was found between these two rating methods with intraclass 
correlation for unique designs: 0.99 and perseverative errors: 0.96. Using the mean and SDS for 
each reference group, we standardized our patient scores by converting it into Z-scores.
 
Statistical analyses
The analyses were all carried out using the PASW (SPSS, Inc., Armonk, NY, USA) statistics 18 pack- 
age. Demographic data are presented as median and interquartile range (IQR), frequencies or per-
centages. We compared data of four groups of patients: 1) patients who received TSS and a three-
field RT technique, 2) patients who received TSS and a four-field RT technique, 3) patients who 
received TSS and a five-field RT technique and 4) patients who only received TSS. Categorical var- 
iables were analyzed by using Chi-square tests. The non-parametric Kruskal-Wallis test was used 
for all continuous variables that failed to meet the normality assumption. The two-tailed alpha 
level of < 0.05 was considered statistically significant. In case of statistical differences between the 






Seventy-five NFA patients (52 men and 23 women, age 61 ± 10 years) participated in this study. 
Thirty patients received TSS and postoperative pituitary RT (RT+ group), whereas 45 patients did 
not receive RT (RT- group). The RT+ group consisted of three RT technique groups; three-field 
technique, n = 10; four-field technique, n = 15; five-field technique, n = 5. Patients’ characteristics 
are given in Table 1. No differences in age at the time of study, sex, or educational level were 
found between the four groups. In our cohort, the older three- and five-field RT techniques were 
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applied earlier in time, and from 2001, these techniques were replaced by a four-field technique. 
Consequently, significant differences between groups were found for average time since RT. Fur-
thermore, patients in the four-field group were on average older at time of RT compared with 
those in the five-field group (Table 1). Hormonal substitution for pituitary deficiencies was similar 
between groups with the exception of thyroid hormone that was given less frequently in patients 
without RT. Feelings of anxiety and depression were comparable between the four groups and 
not indicative of clinical anxiety and depression (data not shown). Social status, full-time/part-
time employment, social security benefit, and comorbidity were all comparable between the four 
groups at the time of assessment (data not shown).
 
Radiotherapy
The RT dose distributions on transversal, coronal and sagittal CT scan images are shown for 
different RT techniques (Figure 1). Estimated RT dosimetric data (derived from Dose-Volume His-
tograms, plots not shown) revealed increased radiation dose exposure in the four-field RT tech-
nique: doses received at 50 and 70% of the hippocampus and PFC were upto seven fold higher 
compared with the three- and five-field RT techniques (Table 2). Furthermore, the patient model 
used in this study had a tumor that had a deviation to the right. Therefore, slightly higher doses 
were found on the right hippocampus compared with the left hippocampus.
Cognitive tests
Cognitive functioning Z-scores are given in Table 2 for memory performance and executive 
functioning. No significant differences were found on the 15 WT and the RFFT between the four 
groups; no RT dose-volume effect on cognition was found. Longer time since RT (three- and five-
field techniques) or older age at RT (four-field technique) did not result in poorer cognitive test 
results. 
  
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     Three-fields technique                   Four-fields technique                   Five-fields technique
Figure 1 The RT dose distributions on transversal, coronal, and sagittal CT scan images are shown for 
different RT techniques. The color areas shown on the CT scan images represent different RT isodose 
areas: red = 49.5-51.8 Gy; orange = 48.2 Gy; green = 42.8 – 45 Gy; light blue = 40 Gy; dark blue = 20 – 30 
Gy; and white = 5-10 Gy. The color lines shown on the CT scan images represent different delineated 
structures: red line, planning target volume; yellow line, gross tumor volume/ pituitary adenoma rem-
nant; light blue line, prefrontal cortex; and pink line, frontal cortex.
 
 Three-fields technique             Four-fields technique         Five-fields technique 
 
 
Figure 1 The RT dose distributions on transversal, coronal, and sagittal CT scan images are shown for 
different RT techniques. The color areas shown on the CT scan images represent different RT isodose 
areas: red = 49.5-51.8 Gy; orange = 48.2 Gy; green = 42.8 – 45 Gy; light blue = 40 Gy; dark blue = 20 – 
30 Gy; and white = 5-10 Gy. The color lines shown on the CT scan images represent different 
deli eated structures: red line, p anning t rget volume; yellow line, gross tumor volume/ pituitary 




Table 2 Estimated dosimetric data memory performance and executive functioning of patients treated 
for nonfunctioning pituitary macroadenoma (NFA) with different radiotherapy (RT) techniques (three, 
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Discussion
This study showed that there were no significant differences between the three-, four- and five 
field RT groups and the non-irradiated patient group. Therefore, a dose-response relationship 
could not be established, even with a radiation dose that was higher on most of the volume of 
the hippocampus and PFC in case of a four-field RT technique compared with the three- and 
five-field techniques.
 To our knowledge, this is the first study that related detailed dosimetric data of pituitary RT to 
cognitive performance. Our results confirm our previous data 13;24 and that of others 14-17 that mod- 
ern dose regimens of pituitary RT does not appear to have a major influence on cognition, but 
also extend these by showing an absence of a relationship between radiation dose and cognitive 
performance. For our study, we used a homogeneous patient group of patients with NFA, thereby 
excluding confounding results by excess hormone or other treatment-related factors 34. Further, 
our study lacks the inherent weakness of studies in patients with primary brain tumors or gliomas. 
Because of the fixed position of the pituitary tumor that is not affecting cortical or subcortical 
areas of the brain, cognitive test results were not influenced by localization of both brain tumor 
and subsequent targeted focal RT.
 This study showed a larger cumulative radiation dose on most of the volume of the left and 
right hippocampus and PFC with a four-field technique. Although this radiation technique was 
developed to circumvent excess radiation exposure to the brain - especially both temporal 
lobes - by avoiding radiation fields overlap, our reconstruction showed that this technique is not 
preferred with regard to RT exposure to the hippocampus and PFC. Despite this excess radiation, 
no poorer cognitive performance was observed in this patient group. Arguably, patients with 
four-field RT had a shorter follow-up time (3 years) when compared with the three- and five-field 
techniques (13 and 12 years respectively). For this reason, cognitive dysfunction may not have 
developed. However, at slightly higher radiation doses, some have reported a decrease in execu-
tive functioning already after 6 months in patients with primary brain tumors 10. It is evident that 
long-term follow-up is necessary for this patient group 4.
 In contrast to our study, Noad et al. found differences between irradiated and non-irradiated 
pituitary patients with regard to cognitive functioning. They tested 71 patients with pituitary tu-
mors treated with surgery with or without RT (25 fractions of 1.8 Gy) on quality of life and sev-
eral cognitive functions (memory, attention and executive functioning) 12. In addition to an im-
pairment in cognitive function regardless of treatment type, they reported a significantly worse 
performance on executive function (measured with the Stroop test) in the RT+ group compared 
with patients receiving only surgery. As noted by the authors, their finding may be explained 
by chance. Jalali et al. 35 also found that RT applied to the left temporal lobe in patients with 
tumors of low malignant potential (craniopharyngioma, cerebellar astrocytoma, optic pathway 
glioma and cerebral low-grade glioma) were predictive of cognitive decline. In addition, Douw et 
al. 36 report a decline in attentional functioning in patients with low-grade gliomas who received 
RT. Among the many differences between these studies and ours, the most explanatory are the 
higher radiation doses used (> 54 Gy in 30 fractions), the different tumor pathology, and the 
young age of the patient group (median 13 years). Comparison with the above mentioned 
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studies 10,35,36 suggests that there may be a kind of threshold for RT to injure the brain and cause 
cognitive impairment. It is likely that only above this threshold a dose-response relationship can 
be found. The age difference between the patients of Jalali’s study and ours is probably also es-
sential, in that a developing brain is more likely to be affected by RT. The absence of a RT dose–
cognitive response relationship in our study suggests that all applied RT techniques seem to 
operate within safe RT dose boundaries.
 In accordance with our finding that pituitary RT was not associated with reduced cognition, 
others also found no differences between patients treated for pituitary tumors with or without RT 
14-17. In a recent review by Loeffler & Shih 37, it was stated that the overall rate of treatment-related 
adverse effects (secondary tumors, visual complications, neurological symptoms, strokes, general, 
and mental health) is low and that only hypopituitarism is to be expected following RT in pituitary 
adenoma patients. However, there are indications that this risk does not exceed the risk on 
hypopituitarism in patients who only received surgery 2. Unfortunately, cognition received little 
attention in this recently published paper by Loeffler. However, Lawrence et al. 4 recently reviewed 
the published data regarding RT-induced brain injury and found very limited evidence that brain 
RT in 2 Gy fractions causes irreversible cognitive decline in adults with primary and metastatic 
brain tumors.
 Some study limitations are to be made. In this study, only a small number of patients were 
included in some subgroups yielding low statistical power and potentially excluding detection 
of differences that were not large. This study showed that there were no significant differences 
on cognitive test performance between the three-, four- and five field RT groups and the non-ir-
radiated patient group. Therefore, it seems plausible that RT might at most have some very subtle 
impact on cognition. However, some reservations are justified. Ideally, to detect such a small size 
effect, a prestudy analytical design with regard to group sizes should be made. Literature provides 
no data on estimated RT-induced cognitive decline in humans with fractionated RT limited to 
a total dose of 45 Gy given in 25 fractions. In addition, the disease prevalence is low (especially 
considering that not all received RT), creating little room for extensive prestudy analytical design. 
Instead, we approached all patients that were eligible within September 2008 and December 
2009, which resulted in a current population size, which is relatively small, and therefore has sta-
tistical limitations.
 Further, it should also be taken into account that it is plausible that not everyone shares the 
same vulnerability to damage of RT. For instance, Armstrong et al. 9 reviewed that the apolipopro-
tein E (ApoE) genotype could prove to be a premorbid risk factor for greater RT-induced damage, 
possibly related to its risk for the development of neurofibrillary tangles and plaque neuritis 38. 
In our group, we found no differences in ApoE genotype between the four groups with normal 
allele frequencies of apoE4. Finally, to precisely define the volume of the hippocampus and PFC, 
we used imaging of a 64-year-old patient. The exact volume of the hippocampus and PFC differs 
inter-individually. As it is a common practice in dosimetric studies, we estimated dosimetric data 
of this model and extrapolated this to our patients.
 Although we found that the multiple field RT techniques do not appear to have a major in-
fluence on cognitive performance, radiotherapeutic treatment techniques continue to develop 
to reduce radiation to healthy tissue. Stereotactic RT (SRT) is one of the new RT techniques and is 
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currently used for the treatment of pituitary tumors in our center. SRT is expected to be a prom- 
ising alternative treatment to deliver the radiation dose precisely. This technique is expected to 
spare normal tissue more than the multiple field external beam RT. The first SRT study results are 
promising according to tumor control and clinical status (including changes in neurological stat- 
us, such as visual function and endocrinological function) at a median follow-up of 25.5 months 
39. Long-term effects on cognitive functioning need to be awaited. In the (nearby) future, alter-
native forms can be expected like hippocampal sparing RT or even limbic circuit sparing, neural 
stem cell sparing, and neural progenitor cell sparing RT 5-7. This may be especially important for 
patients with benign tumors, with a long life expectancy like NFA patients.
 In conclusion, no dose-response relationship could be established, confirming that current 
multiple field RT techniques and fractionated radiation dose regimens do not result in major 
differences in cognitive performance involving the hippocampus and PFC in NFA patients.
 
Declaration of interest




This research did not receive any specific grant from any funding agency in the public, commer-
cial or not-for-profit sector.
 
Acknowledgements
We like to thank Dr. W.J. Sluiter for his help with the statistical analyses. The help of A. Klop is 
greatly appreciated. We thank Rob Bieringa, Joost Keers, René Oostergo, Rosalie Visser, Judith 
Vonk for their work related to data-collection and validation of the RFFT norm scores derived from 
the LifeLines cohort study. The authors are grateful to the study participants, the staff from the 
LifeLines Cohort Study and Medical Biobank Northern Netherlands, and the participating general 
practitioners and pharmacists. LifeLines Cohort Study: the LifeLines Cohort Study, and generation 
and management of GWAS genotype data for the LifeLines Cohort Study is supported by the 
Netherlands Organization of Scientific Research NWO (grant 175.010.2007.006), the Economic 
Structure Enhancing Fund (FES) of the Dutch government, the Ministry of Economic Affairs, the 
Ministry of Education, Culture and Science, the Ministry for Health, Welfare and Sports, the Nor-
thern Netherlands Collaboration of Provinces (SNN), the Province of Groningen, the University 
Medical Center Groningen and the University of Groningen, the Dutch Kidney Foundation and 




Erridge SC, Conkey DS, Stockton D, Strachan MW, Statham PF, Whittle IR, Grant R, Kerr GR, Gregor A. 2009 Radiotherapy 
for pituitary adenomas: long-term efficacy and toxicity. Radiotherapy and Oncology: journal of the European Scoiety for 
the Therapeutic Radiotheapy and Oncology 93 597-601.
van den Bergh AC, van den Berg G, Schoorl MA, SLuiter WJ, van der Vliet AM, Hoving EW, Szabó BG, Langendijk JA, 
Wolffenbuttel BH, Dullaart RP. 2007 Immediate postoperative radiotehrapy in residual nonfunctioning pituitary ade-
noma: beneficial effect on local control without additional negative impact on pituitary function and life expectancy. 
International Journal of Radiation Oncology, Biology, Physics 67 863-869.
Gittoes NJ. 2005 Pituitary radiotherapy: current controversies. Trends in Endocrinology and Metabolism 16 407-413.
 
Lawrence YR, Li XA, el Naqa I, Hahn CA, Marks LB, Merchant TE, Dicker AP. 2010 Radiation dose-volume effects in the 
brain. International Journal of Radiation Oncology, Biology, Physics 76 S20-S27.
Gondi V, Tome WA, Mehta MP. 2010 Why avoid the hippocampus? A comprehensive review. Radiotherapy and 
Oncology: journal of the European Scoiety for the Therapeutic Radiotherapy and Oncology 97 370-376.
Marsh JC, Gielda BT, Herskovic AM, Abrams RA. 2010 Cognitive Sparing during the Administration of Whole Brain 
Radiotherapy and Prophylactic Cranial Irradiation: Current Concepts and Approaches. Journal of Oncology 198208.
Redmond KJ, Achanta P, Grossman SA, Armour M, Reyes J, Kleinberg L, Tryggestad E, Quinones-Hinojosa A, Ford EC. 2011 
A radiotherapy technique to limit dose to neural progenitor cell niches without compromising tumor coverage. Journal 
of Neurooncology 104 579-87.
Armstrong CL, Hunter JV, Ledakis GE, Cohen B, Tallent EM, Goldstein BH, Tochner Z, Lustig R, Judy KD, Pruitt A, Mollman 
JE, Stanczak EM, Jo MY, Than TL, Phillips P. 2002 Late cognitive and radiographic changes related to radiotherapy: initial 
prospective findings. Neurology 59 40-48.
Armstrong CL, Gyato K, Awadalla AW, Lustig R, Tochner ZA. 2004 A critical review of the clinical effects of therapeutic 
irradiation damage to the brain: the roots of controversy. Neuropsychology Review 14 65-86.
Hahn CA, Zhou SM, Raynor R, Tisch A, Light K, Shafman T, Wong T, Kirkpatrick J, Turkington T, Hollis D, Marks LB. 2009 
Dose-dependent effects of radiation therapy on cerebral blood flow, metabolism, and neurocognitive dysfunction. 
International Journal of Radiation Oncology, Biology, Physics 73 1082-1087.
Surma-aho O, Niemelä M, Vilkki J, Kouri M, Brander A, Salonen O, Paetau A, Kallio M, Pyykkönen J, Jääskeläinen J. 2001 
Adverse long-term effects of brain radiotherapy in adult low-grade glioma patients. Neurology 56 1285-1290.
Noad R, Narayanan KR, Howlett T, Lincoln NB, Page RC. 2004 Evaluation of the effect of radiotherapy for pituitary 
tumors on cognitive function and quality of life. Clinical Oncology (Royal College of Radiologists (Great Britain)) 16 233-
237.
van Beek AP, van den Bergh AC, van den Berg LM, van den Berg G, Keers JC, Langendijk JA, Wolffenbuttel BH. 2007 
Radiotherapy is not associated with reduced quality of life and cognitive function in patients treated for nonfunctio-
ning pituitary adenoma. International Journal of Radiation Oncology, Biology, Physics 68 986-991.
Guinan EM, Lowy C, Stanhope N, Lewis PD, Kopelman MD. 1998 Cognitive effects of pituitary tumors and their 

















Pituitary radiotherapy and cognition
McCord MW, Buatti JM, Fennell EM, Mendenhall WM, Marcus RB, Rhoton AL, Grant MB, Friedman WA. 1997 Radiothe-
rapy for pituitary adenoma: long-term outcome and sequelae. International Journal of Radiation Oncology, Biology, 
Physics 39 437-444.
Peace KA, Orme SM, Thompson AR, Padayatty S, Ellis AW, Belchetz PE. 1997 Cognitive dysfunction in patients treated 
for pituitary tumors. Journal of Clinical and Experimental Neuropsychology 19 1-6.
Peace KA, Orme SM, Padayatty SJ, Godfrey HP, Belchetz PE. 1998 Cognitive dysfunction in patients with pituitary 
tumor who have been treated with transfrontal or transsphenoidal surgery or medication. Clinical Endocrinology (Oxf ) 
49 391-396.
Abayomi OK. 2002 Pathogenesis of cognitive decline following therapeutic irradiation for head and neck tumors. Acta 
Oncologica 41 346-351.
Addis DR, Moscovitch M, McAndrews MP. 2007 Consequences of hippocampal damage across the autobiographical 
memory network in left temporal lobe epilepsy. Brain 130 2327-2342.
Pereira AG, Portuguez MW, da Costa DI, Azambuja LS, Marroni SP, da Costa JC, Pereira-Filho AA. 2011 Route Learning 
Performance: Is it a Hippocampus Function? Cognitive and Behavioral Neurology: official journal of the Society for Beha-
vioral and Cognitive Neurology 24 4-10.
Monje ML, Palmer T. 2003 Radiation injury and neurogenesis. Current Opinion in Neurology 16 129-134.
Shallice T, Burgess P. 1996 The domain of supervisory processes and temporal organization of behaviour. Philosophi-
cal Transactions of the Royal Society of London. Series B Biological Sciences 35 1405-1411.
Miller EK, Cohen JD. 2001 An integrative theory of prefrontal cortex function. Annual Review of Neuroscience 24 167-202.
Brummelman P, Elderson MF, Dullaart RP, van den Bergh AC, Timmer CA, van den Berg G, Koerts J, Tucha O, 
Wolffenbuttel BH, van Beek AP. 2011 Cognitive functioning in patients treated for nonfunctioning pituitary macroa-
denoma and the effects of pituitary radiotherapy. Clinical Endocrinology (Oxf ) 74 481-487.
Gazzaniga M, Ivry R, Mangun R. 2002 In Cognitive Neuroscience, edn 2, New York: W W Norton & Company, p75, 501.
Martin J. 1996 In Neuroanatomy Text and Atlas, edn 2, Stamford, CT: Appleton and Lange.
Yushkevich PA, Wang H, Pluta J, Das SR, Craige C, Avants BB, Weiner MW, Mueller S. 2010 Nearly automatic segmenta-
tion of hippocampal subfields in in vivo focal T2-weighted MRI. Neuroimage 53 1208-1224.
van der Elst W, Van Boxtel MP, Van Breukelen GJ, Jolles J. 2005 Rey’s verbal learning test: normative data for 1855 
healthy participants aged 24-81 years and the influence of age, sex, education, and mode of presentation. Journal of 
the International Neuropsychological Society 11 290-302.
Ruff RM, Light RH, Evans RW. 1987 The Ruff Figural Fluency Test: A normative study with adults. Developmental 
neuropsychology 3 37-51.




















Spinhoven P, Ormel J, Sloekers PP, Kempen GI, Speckens AE, Van Hemert AM. 1997 A validation study of the Hospital 
Anxiety and Depression Scale (HADS) in different groups of Dutch subjects. Psychological Medicine 27 363-370.
Stolk RP, Rosmalen JG, Postma DS, de Boer RA, Navis, G, Slaets JP, Ormel J, Wolffenbuttel BH. 2008 Universal risk factors 
for multifactorial diseases: LifeLines: a three-generation population-based study. European Journal of Epidemiology 23 
67-74.
Duncan DB. 1955 Multiple range and multiple F tests. Biometrics 11 1-42.
Tiemensma J, Kokshoorn NE, Biermasz NR , Keijser BJ, Wassenaar MJ, Middelkoop HA, Pereira AM, Romijn JA. 2010 
Subtle cognitive impairments in patients with long-term cure of Cushing’s disease. Journal of Clinical Endocrinology 
and Metabolism 95 2699-2714.
Jalali R, Mallick I, Dutta D, Goswami S, Gupta T, Munshi A, Desphande D, Sarin R. 2010 Factors influencing neurocog-
nitive outcomes in young patients with benign and low-grade brain tumors treated with stereotactic conformal 
radiotherapy. International Journal of Radiation Oncology, Biology, Physics 77 974-979.
Douw L, Klein M, Fagel SS, van den Heuvel J, Taphoorn MJ, Aaronson NK, Postma TJ, Vandertop WP, Mooij JJ, Boerman 
RH, Beute GN, Sluimer JD, Slotman BJ, Reijneveld JC, Heimans JJ. 2009 Cognitive and radiological effects of radiothe-
rapy in patients with low-grade glioma: long-term follow-up. Lancet Neurology 8 810-818.
Loeffler JS, Shih HA. 2011 Radiation Therapy in the Management of Pituitary Adenomas. Journal of Clinical Endocrino-
logy and Metabolism 96 1992-2003.
Thaker U, McDonagh AM, Iwatsubo T, Lendon CL, Pickering-Brown SM, Mann DM. 2003 Tau load is associated with 
apolipoprotein E genotype and the amount of amyloid beta protein, Abeta40, in sporadic and familial Alzheimer’s 
disease. Neuropathology and Applied Neurobiology 29 35-44.
Hashizume C, Mori Y, Kobayashi T, Shibamoto Y, Nagai A, Hayashi N. 2010 Stereotactic radiotherapy using Novalis for 











Cognitive functioning in patients
Cognitive performance and brain 
abnormalities on MRI in patients treated 




Pauline Brummelman, Margriet G.A. Sattler, Linda C. Meiners, Gerrit van den 
Berg, Melanie M. van der Klauw, Martin F. Elderson, Robin P.F. Dullaart, Janneke 
Koerts, Oliver Tucha, Bruce H.R. Wolffenbuttel, Alfons C.M. van den Bergh and 







Cognition and MRI abnormalities
Abstract
 
Objective The extent to which cognitive dysfunction is related to specific brain abnormalities in 
patients treated for pituitary macroadenoma is unclear. Therefore, we compared brain abnormal- 
ities seen on Magnetic Resonance Imaging (MRI) in patients treated for nonfunctioning pituitary 
macroadenoma (NFA) with or without impairments in cognitive functioning.
Methods In this cross-sectional design, a cohort of 43 NFA patients was studied at the University 
Medical Center Groningen. White matter lesions (WMLs), cerebral atrophy, (silent) brain infarcts 
and abnormalities of the temporal lobes and hippocampi were assessed on pre-treatment and 
post-treatment MRI scans. Post-treatment cognitive examinations were performed using a verbal 
memory and executive functioning test. We compared our patient cohort with large reference 
populations representative of the Dutch population.
Results One or more impairments on both cognitive tests were frequently observed in treated 
NFA patients. No treatment effects were found with regard to the comparison between patients 
with and without impairments in executive functioning. Interestingly, in patients with one or 
more impairments on verbal memory function, treatment with radiotherapy had been given 
more frequently (74% in the impaired group versus 40% in the unimpaired group, P = 0.025). Pa-
tients with or without any brain abnormality on MRI did not differ in verbal memory or executive 
functioning.
Conclusions Brain abnormalities on MRI are not observed more frequently in treated NFA pa-
tients with impairments compared to NFA patients without impairments in verbal memory or 





















A nonfunctioning pituitary macroadenoma (NFA) is a benign tumor of the pituitary gland. Its 
treatment usually consists of pituitary surgery sometimes followed by radiotherapy (RT) in case 
of incomplete resection or tumor recurrence. Despite the benefits of postoperative RT regarding 
local control 1,2, concerns related to brain abnormalities and diminished cognitive performance 
have questioned the safety of RT.
 In patients with low grade glioma, white matter lesions (WMLs) and cerebral atrophy are well 
known radiologically detectable abnormalities of the brain after RT. Furthermore, there appears 
to be a correlation between radiologic abnormalities and cognitive performance 3,4. One prospec- 
tive study found that cognitive performance of irradiated patients with recurrent malignant 
glioma may be more sensitive in predicting tumor progression than the MR images, because 
cognitive performance predicted tumor recurrence more than a month earlier than MRI confir-
mation 5. Although the aforementioned studies suggest a relation between brain abnormalities 
and cognitive performance, a shortcoming of many imaging studies in relation to cognition is 
that they focused on patients without fixed tumor localizations 3-6. Consequently, different cogni-
tive domains will be affected by the tumor itself leading to heterogeneous results in brain tumor 
patients. In contrast, NFA patients compared to primary brain tumor patients (1) have a fixed 
tumor position, (2) are treated with a lower radiation dose and (3) have no exposure of (other) 
disease- and treatment related factors, such as chemotherapy. This offers a unique opportunity to 
study cognition and radiological brain abnormalities without these confounding factors.
 Although we previously found that NFA patients (tested between September 2008 and De-
cember 2009) score significantly worse on cognition compared to reference samples, we did 
not find a relation between RT and cognitive performance 7,8. It is, however, possible that brain 
abnormalities are related to cognitive performance. Up to date, there are no studies on such rela-
tionships in patients with a fixed tumor localization within one part of the brain who are treated 
with relatively low radiation doses. Therefore, the main objective of this follow-up study was to 
assess and compare cognition and brain abnormalities as shown by MRI in treated (surgery with 




A total of 43 NFA patients (28 males and 15 females, aged 61 ± 10 years , range 40 – 81 years at 
time of cognitive assessment) underwent treatment between August 1987 and May 2008, and 
were evaluated by using cognitive tests and MRI scans at the University Medical Center Groning- 
en (UMCG). All patients were treated with surgery as the primary treatment modality with or 
without postoperative RT. The diagnosis of NFA was based on the patient’s clinical history and 
presentation, endocrine evaluation, MR imaging, and was confirmed in all patients by postopera-
tive histopathological findings. Pre- and post-treatment MRI scans were available for all patients. 
The pre-treatment scans were made prior to surgery. To assure that acute and early-delayed post-
treatment effects had resolved, patients underwent cognitive testing if surgery or RT was at least 
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6 months ago and if their hormone replacement schedules were stable during these preceding 
months. All patients had regular follow-up appointments in our endocrine or radiotherapy out-
patient clinic. Patients were followed with MRI scans from the onset of diagnosis until November 
2010. Approval was given by the medical ethics review committee of the UMCG.
Cognitive tests
Aspects of verbal memory were assessed with the 15 Words Test (15 WT) which is a Dutch equiv- 
alent of the Rey Auditory Verbal Learning Test 9. In this test, 15 words were presented five times. 
After each trial, patients were asked to name immediately the words they remembered. This 
allowed the calculation of three different scores describing immediate memory:
1. The short-term memory score is based on the number of words patients were able to name after 
the first presentation of the word list.
2. The total memory score represents the total number of words patients remembered over the 
five trials.
3. The learning score describes the difference between the number of words remembered in the 
third trial in comparison with the first trial.
Besides immediate memory, delayed memory was measured.
4. The delayed memory score is based on the number of words patients could recall after a period 
of about 30 minutes.
 Executive functioning was assessed using the Ruff Figural Fluency Test (RFFT) 10. In this test, 
patients were presented with sheets of paper on which 35 squares were printed, each with a fixed 
pattern of five dots. The test consisted of five parts, which differed with regard to the designs. 
While the configurations of dots are the same in the first three parts of the test, two types of 
distractions are added in two of these parts. In the last two parts the configurations of the dots 
are different and without distractions. The participant was asked to produce as many different 
designs as possible by connecting two or more dots in each square with straight lines. The time 
for each part was restricted to 1 minute so that the total test time was 5 minutes. Responses were 
scored with regard to the total number of unique designs generated over the five parts. The per-
severative errors score represents the total number of repetitions of the same design drawn. The in-
terrater variability (two independent raters) was determined by Pearson’s r and was 0.99 for both 
total unique designs and perseverative errors. The error ratio is calculated by the total number of 
perseverative errors divided by the total number of unique designs.
 
Questionnaires and protocol
A common questionnaire on demographic and health related data was used with special atten-
tion for educational level, social status, full-time/part-time employment, social security benefit, 
comorbidity, use of medication, cardiovascular risk factors, traumatic brain injury and dementia. 
Education level was determined by using a Dutch education system, comparable to the Interna-
tional Standard Classification of Education (ISCED) 11. This scale ranges from 1 (elementary school 
not finished) to 7 (university level).
 The Hospital Anxiety and Depression Scale (HADS) consists of 14 items and measures anxiety 
and depression 12. Each item is scored as a number, with a maximum score for each subscale 
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(anxiety or depression) of 21. Higher scores indicate more severe anxiety or depression.
 In fixed order, the test protocol was as follows: (1) the 15 WT: direct recall, (2) the RFFT, (3) a 
common questionnaire to assess baseline information, (4) physical examination: height, weight, 
blood pressure, waist circumference, hip circumference and compliance to the test situation 
(5) the HADS and finally (6) the 15 WT: delayed recall. The assessment took approximately forty 
minutes and was performed directly after or just before the regular outpatient visit. All testing and 
scoring of tests were performed by trained personnel.
Reference data: healthy control subjects
The performances of patients were compared with Dutch controls. Normative data for the HADS 
were derived from Spinhoven et al. 12. In their study, psychometric properties of the HADS were 
assessed in six different groups of Dutch subjects (n = 6165): (1) a random sample of younger 
adults (18-65 years) (n = 199); (2) a random sample of elderly subjects of 57 to 65 years of age (n 
= 1901); (3) a random sample of elderly subjects of 66 years and older (n = 3293); (4) a sample 
of consecutive general practice patients (n = 112); (5) a sample of consecutive general medical 
out-patients with unexplained somatic symptoms (n = 169); and (6) a sample of consecutive psy-
chiatric out-patients (n = 491). In all six groups, an authorized Dutch translation of the HADS was 
used. General population mean and standard deviation scores were used from 18 to 65 years and 
>65 years to calculate Z-scores.
 Reference data for the 15 WT were derived from control subjects of the Maastricht Aging 
Study. In this cohort, 1780 healthy participants between 24 and 81 years were evaluated on a 
Dutch adaptation of the Rey Verbal Learning Test, the 15 WT 9. Regressions models given by the 
authors were used to determine accurate Z-scores. The final test scores were controlled for age, 
sex, and education. Reference data for the RFFT were derived from a sample (n = 10,289) of the 
LifeLines Cohort Study 13. Reference groups were stratified by a matrix of eight education levels 
and 13 age levels (half decades from 20 to 85 years). Each cluster consisted on average of 120 
subjects. RFFT forms were analyzed by a computerized pattern recognition program. There was 
a good internal consistency (n=373) between computerized rating and human rating for unique 
designs (Cronbach’s α = 0.99) and perseverative errors (Cronbach’s α = 0.97). Using a Bland-Alt-
man analysis, a near perfect level of agreement was found between these two rating methods 
with intraclass correlation for unique designs of 0.99 and perseverative errors of 0.96. Using the 
mean and standard deviation scores for each reference group, we standardized our patient scores 
by converting them into Z-scores.
 
MRI scans
The pre- and post-treatment MRI scans were all obtained from the Department of Radiology at 
the UMCG from the period July 1987 to November 2010. The MRI scans were primarily done for 
clinical diagnosis of the NFA and post-treatment follow-up. All patients underwent MRI scanning 
at the UMCG following a standard protocol. The scans were made on a 1 Tesla system using a 
regular head coil. The standard scan protocol consisted of coronal T2, and coronal and sagittal T1 
of the region of the pituitary gland. On the coronal T2 images the white matter of the frontal and 
temporal lobes were assessed, as well as the hippocampi and the frontal and temporal horns and 
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the peripheral cerebrospinal fluid (CSF) spaces. The total number of MRI scans per patient was on 
average 7 (interquartile range (IQR) 5-8). The median duration of MRI scan follow-up was 6 years 
(IQR 3-9 years).
 
Rating of MRI abnormalities
MRI scans were presented randomly and rated by an experienced neuroradiologist (LM) blinded 
to the clinical data and treatment. The coronal T2 weighted images were used for the assessment 
of WMLs and central and peripheral CSF spaces (atrophy), (silent) brain infarcts, and any abnor-
malities of the temporal lobes and left and right hippocampus.
 WMLs were defined as subcortical or periventricular focal or confluent areas of abnormal high 
signal intensity on T2 in the white matter. Cerebral (central and peripheral) atrophy was determined 
by assessing an increase in the peripheral CSF spaces with an increase in the width of the sulci, 
loss of parenchyma, and dilatation of the lateral and third ventricles. A four point visual rating 
scale (0-3) was used to assess the severity of the cerebral atrophy (i.e. sulcal and ventricular en-
largement): (0) normal, (1) minimal (slightly prominent peripheral CSF spaces, normal ventricles), 
(2) moderate (prominent peripheral CSF spaces, slightly enlarged ventricles), (3) severe (marked 
prominence of peripheral CSF spaces, marked increase in size of ventricles) 14. Cerebral atrophy 
was rated on T2-weighted MRI scans. Brain infarcts (silent and symptomatic) were rated as present 
or absent and defined as larger areas of T2 hyperintense gliosis or focal tissue loss with the same 
intensity as cerebrospinal fluid on T1 or T2 weighted MR images. Furthermore, any MRI abnormali-




All statistical analyses were performed using Statistical Package for the Social Sciences (SPSS, Inc., 
Armonk, NY, USA), version 20. Demographic data are presented as median, IQR, frequencies or 
percentages. Since not all data were normally distributed, patients’ cognitive performances were 
compared with the reference group by using non-parametric tests. Cognitive performance data 
were presented as mean Z-score with a non-parametric 95% confidence interval (CI) 15. Further-
more, the number of patients scoring in the impaired range was presented. According to Lezak, 
cognitive impairment on a test was defined as a performance equivalent to or below the 10th 
percentile of the reference samples (equivalent to a Z-score of ≤ -1.3) 16. Categorical variables 
(e.g. the presence or absence of radiological brain abnormalities) were analyzed using Chi-square 
test. Continuous variables were analyzed by the Mann-Whitney test. The two-tailed alpha level of 




A total of 43 NFA patients were evaluated for cognitive functioning and brain abnormalities on 
MRI scans. The clinical characteristics of these patients are shown in Table 1. All patients under-
went primary surgery, 36 patients (84%) by transsphenoidal resection and 7 patients (16%) by 
  
Chapter 4
craniotomy. Twenty-five patients (58%) were treated with postoperative pituitary RT (with a 
median time of seven months after initial surgery).
 Of the irradiated patients, twenty-three patients (92%) received daily radiation fractions of 1.8 
Gray (Gy) and two patients (8%) received daily radiation fractions of 2 Gy. The total radiation dose 
was: 45 Gy (n = 21, 84%), 46 Gy (n = 2, 8%) or 50.4 Gy (n = 2, 8%). The RT techniques were: two-field 
(n = 1, 4%), three-field (n = 12, 48%), four-field (n = 3, 12%), five-field (n = 5, 20%), a combination 
of two-field and three-field (n = 2, 8%) or a combination of two-field and five-field (n = 2, 8%).
 Thirty-eight patients (88%) received single or multiple hormone replacement therapy (Table 1).
 
Cognitive functioning in the whole patient group (n = 43)
Results for cognitive function tests are shown in Table 2. There were no significant differences in 
Z-scores between the irradiated and non-irradiated patients for the verbal memory and executive 
functioning subscores (data not shown).
 
Cognitive impairments in patients with or without any brain abnormalities on MRI
Table 3 presents the number of patients with an impaired performance on verbal memory (n = 
23, 53%) and executive functioning (n = 19, 44%) divided into a group of patients with no brain 
abnormalities on MRI versus any brain abnormality on MRI. With regard to the 4 patients with no 
brain abnormalities on MRI and impaired functioning of verbal memory or executive functioning, 
there was no overlap in the patients, except for one.
 
MRI abnormalities in patients with or without cognitive impairments
The characteristics of the MRI abnormalities in NFA patients with or without impairments on 
verbal memory and executive functioning are given in Table 4 and 5. No differences were seen 
between both patient groups for WMLs, cerebral atrophy, and abnormalities in temporal lobes 
or hippocampi. In each group one brain infarct was noted. Also no difference was seen in type 
of surgery (transsphenoidal surgery or craniotomy) and hormonal substitution therapy for both 
memory performance and executive functioning. However, patients who received RT had signifi-
cantly more often impairments in verbal memory compared with patients who had not received 
RT. In multivariate analyses this finding remained significant when corrected for other treatment 
characteristics (data not shown).
  
Cognition and MRI abnormalities
Table 1. Clinical characteristics of patients treated for a nonfunctioning pituitary adenoma, n = 43
Table 1. Clinical characteristics of patients treated for a nonfunctioning pituitary adenoma, n=43 
 
Basic characteristics  
Age at cognitive assessment (y), median [IQR] 60 [56; 70]  
Sex (male/female) 28/15 
Educational level (1/2/3/4/5/6/7) (number) 1/4/0/9/18/9/2 
Surgery (%) 100 
Transsphenoidal surgery/ Craniotomy (%)  84/16 
Age at surgery (y), median [IQR] 49 [40; 55]  
Time between surgery and cognitive test performance (y), median [IQR] 11 [6; 15] 
Patients with 2nd surgery (%)  7 
Radiotherapy (%) 58 
Age at radiotherapy (y), median [IQR] 48 [41; 56] 
Time between radiotherapy and cognitive testing (y), median [IQR] 13 [9; 19] 
MRI scans 
Age at the last MRI scan (y), median [IQR] 
 
58 [55; 65] 
Time between cognitive test performance and last MRI scan (y), median [IQR] 1.3 [0.6; 2.5] 
No. of hormonal replacements (0/1/2/3/4/5) (5/9/8/13/8/0) 
Glucocorticoids (% of patients substituted)  63 
Thyroid hormone (% of patients substituted)  72 
Growth hormone (% of patients substituted) 21 
Sex hormone (% of patients substituted) 58 
Desmopressin (% of patients substituted) 9 
IQR: Interquartile range. Education level was determined by using a Dutch education system, compa- 
rable to the International Standard Classification of Education11. This scale ranges from 1 (elementary  





Table 2. Cognitive performance of patients treated for nonfunctioning pituitary macroadenoma, n = 43
Table 3. Cognitive impairments in patients with or without any brain abnormalities on MRI.










N = 34 
P-value 
Age characteristics     
Age at cognitive assessment (y), median [IQR] 57 [49; 61]      62 [58; 70]                 0.092 
Age at the last MRI scan (y), median [IQR] 56 [48; 60]  60 [55; 69]  0.159 
Cognitive functioning      
Impaired functioning on verbal memory (yes/no) 







Impaired functioning on executive functioning 







Table 2. Cognitive performance of patients treated for nonfunctioning pituitary macroadenoma, n = 43 
 Median [IQR] 95% CI of  
the median 
Score ≤ 10  
perc. N (%) 
 P-value* 
Verbal Memory  
15 Words Test 
    
Short-term memory -0.29 [ -0.79; 0.08] -0.63; -0.03   9 (21)   0.03 
Total memory -0.80 [-1.20; -0.30] -1.12; -0.39  14 (33) <0.001 
Learning score -0.32 [-0.76; 0.07] -0.58; 0.11  7 (16)  0.18 
Delayed memory -0.90 [-1.20; -0.10]  -1.04; -0.30 14 (33) <0.001 
Executive functioning  
RFFT 
    
Unique designs -0.93 [-1.35; -0.10] -1.15; -0.32 17 (40) <0.001 
Perseverative errors -0.71 [-1.06; 0.15] -0.65; 0.61  8 (19)  0.95 
Error ratio      -0.40 [-1.00; 0.21]       -0.59; 0.43  8 (19)        0.76 
Cognitive performance data are given as Z-scores median and Interquartile range [IQR] 
CI: Confidence Interval 
*P-values of the 95% CI compared to the reference data 
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Table 4. Comparison of MRI abnormalities between patients with or without impairments on verbal 
memory.
Table 5. Comparison of MRI abnormalities between patients with or without impairments on execu-
tive functioning.
Table 4. Comparison of MRI abnormalities between patients with or without impairments on verbal memory.  
 Impaired patients 
N = 23 
 Unimpaired patients 
N = 20 
P-value 
 Number (frequency, (%))  Number (frequency, (%))   
Radiological Abnormalities       

























Transsphenoidal surgery/ craniotomy 18/5 (78/22)  18/2 (90/10)  0.298 
Radiotherapy (yes/no) 17/6 (74/26)  8/12 (40/60)  0.025 
Hormonal replacement      
Glucocorticoids (yes/no) 17/6 (74/26)  14/6 (70/30) 0.775  
Thyroid hormone (yes/no) 17/6 (74/26)  13/7 (65/35) 0.526  
Growth hormone (yes/no) 6/17 (26/74)  5/15 (25/75) 0.935  
Sex hormone (yes/no) 15/8 (65/35)  13/7 (65/35) 0.988  
Desmopressin (yes/no) 3/20 (13/87)  1/19 (5/95) 0.365  
 
 






 Impaired patients 
N = 19 
 Unimpaired patients 
N =24 
P-value 
 Number (frequency, (%))  Number (frequency, (%))   
Radiological Abnormalities      




























Transsphenoidal surgery/ craniotomy 15/4 (79/21)  21/3 (88/12) 0.451  
Radiotherapy (yes/no) 12/7 (63/37)  13/11 (54/46) 0.553  
Hormonal replacement      
Glucocorticoids (yes/no) 15/4 (79/21)  16/8 (67/33) 0.373  
Thyroid hormone (yes/no) 16/3 (84/16)  14/10 (58/42) 0.067  
Growth hormone (yes/no) 6/13 (32/68)  5/19 (21/79) 0.423  
Sex hormone (yes/no) 13/6 (68/32)  15/9 (63/37) 0.686  




This study confirms that impairments in verbal memory and executive functioning are frequently 
observed in treated NFA patients. However, patients with and without cognitive impairments did 
not differ with respect to brain abnormalities on MRI.
 To our knowledge, this is the first study that related cognitive functioning to abnormalities 
in the brain on MRI in a patient group with a fixed position of the tumor. We recruited patients 
with NFA only, thereby excluding confounding variables such as tumor malignancy and diffuse 
brain tumor localization which affect different brain regions and hence cognitive functioning. 
Previously, we found no negative effects of RT in NFA patients on quality of life and objective and 
self-rated cognitive performance compared to reference populations 7, 17. These results were ex-
tended, by showing an absence of a relationship between cognitive performance and radiation 
dosimetry 8. In the present study, 79% of NFA patients had an abnormality on MRI, although these 
brain abnormalities were not more frequently observed in patients with cognitive impairments. 
Interestingly, patients who received RT suffered significantly more often from impairments of 
verbal memory. The differences between our previous findings on the effects of RT and this study 
can be explained by the fact that a cognitive impairment in the present study was defined as 
at least one impairment for the total domain of memory, while our previous studies compared 
impairments for memory subscores 7,8. However, both studies demonstrate that patients show 
memory impairments more often compared to the reference population.
 In addition to RT, other factors, like surgery, the pituitary disease itself or hormonal abnormal- 
ities secondary to the tumor and/or its treatment may lead to impaired cognitive functioning 
in treated NFA patients 18. With respect to hormonal abnormalities, glucocorticoids and thyroid 
substitution therapy are of particular importance for cognitive functioning 19-21. Glucocorticoids 
may play an important role in the regulation of memory 19. In addition to memory, we found that 
glucocorticoids might also affect other domains of cognition, such as executive functioning, at-
tention and social cognition (P Brummelman, J Koerts, RPF Dullaart, G van den Berg, MM van der 
Klauw, O Tucha, BHR Wolffenbuttel & AP van Beek, unpublished observations). Regarding thyroid 
substitution therapy, research in congenital hypothyroid patients or hypothyroidism in adulthood 
has shown the importance of thyroid hormone for cognition 20, 21. Although we found no signif- 
icant differences between these hormonal substitution therapies and impaired performances 
in memory and executive functioning, a more extensive neuropsychological test battery might 
provide more information regarding the relation between hormonal substitution therapy and 
cognitive functioning.
 Several limitations need to be addressed. First, the coronal T2 images used for the assess-
ment provide a limited view of the cerebral hemispheres. However, complications which may 
be associated with surgical and RT treatment for NFA patients would be expected in the frontal 
and temporal lobes, which are depicted on these images. Second, the patients differed in time 
interval between cognitive test performance and last MRI scan. However, we found no effects 
of this time interval on the cognitive outcome measures and the presence or absence of brain 
abnormalities.
 The potential damaging effect of treatment on cognitive functioning is an important factor 
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in the determination of the risks versus benefits of treatment, and therefore an important part of 
clinical decision making. Since more than 90% of patients with brain tumors have cognitive im-
pairments at baseline 22, there is need for prospective studies to establish the effects of treatment 
on cognitive functioning and radiological brain abnormalities. These prospective studies with 
pre- and post-treatment assessments (MRI scans and cognitive test performance) would inform 
us about the causal relationship between treatment induced brain damage and cognitive func-
tioning, allowing the discrimination of disease- and treatment related factors.
 From this study it is evident that patients can experience complaints in memory and execu-
tive functioning which might have vast consequences on the patients’ everyday lives (e.g. they 
find difficulties in managing the day). Clinicians have to be aware that the absence of abnormal- 
ities on MRI does not exclude impairments of cognition. Cognitive rehabilitation therapy can be 
applied to those patients who suffer from cognitive impairments in their daily lives in order to 
develop compensatory techniques for the management of their lives.
 In conclusion, brain abnormalities on MRI are not more frequently observed in treated NFA 
patients with impairments of verbal memory or executive functioning than in patients without 
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Background In untreated acromegaly patients, decreased cognitive functioning is reported to 
be associated with the degree of growth hormone (GH) and IGF-1 excess. Whether previous GH 
excess or current medical treatment for acromegaly specifically affects cognition remains unclear. 
The aim of this study was to compare cognitive functioning of patients who are treated for acro-
megaly with patients with nonfunctioning pituitary adenomas (NFA). In addition, we assessed the 
influence of prolonged medical treatment after initial transsphenoidal surgery on cognition.
 
Design In this cross-sectional study, 74 patients participated, who were treated for acromegaly 
(n = 50; median [interquartile range] age: 53 [45-65] years) or NFA (n = 24; age: 63 [59-70] years). 
The NFA patients were selected for a high likelihood of normal GH secretion based on an IGF-1 Z-
score within the normal range (> -2) and zero or one axis substituted. Of the acromegaly patients, 
28 had achieved remission, while 22 were biochemically controlled with long-acting somato- 
statin analogues and/or pegvisomant. Memory and executive functioning were assessed by the 
15 Words Test and the Ruff Figural Fluency Test, and reported as Z-scores.
 
Results The total patient group scored significantly poorer than the reference population on 
memory and executive functioning (P < 0.001). However, cognitive test performance was not sig-
nificantly different between acromegaly patients with a persistent disease, acromegaly patients 
in remission and NFA patients.
 
Conclusion The total patient group scored worse compared with reference populations. We 
found no association between previous GH excess and cognition. In addition, current medical 







Changes in cognitive functioning can be expected as a consequence of growth hormone (GH) 
excess, or GH deficiency. The reason for this assumption is a wide distribution of binding sites 
for Insulin-like growth factor-1 (IGF-1) in the brain in particular in the medial temporal lobe (the 
hippocampus) and in the prefrontal cortex (PFC) 1. Indeed, studies on the effects of GH and IGF-1 
on cognition performed in GH deficient patients demonstrated a link between GH and cognitive 
performance, where poor performance was ameliorated with GH treatment 2-4.
 In acromegaly, which is characterized by excess GH production, cognitive functioning is also 
reported to be impaired. In a recent study, Leon-Carrion et al. 5 compared patients with active 
acromegaly with healthy participants. They found a moderate to severe memory impairment in 
patients and postulated that high levels of GH and IGF-I in acromegaly patients could be the basis 
for these findings. However, comparisons with untreated acromegaly patients are less informa-
tive because nonspecific psychological factors associated with chronic illness will undoubtedly 
influence the results 6. In another study, Sievers and colleagues compared acromegaly patients (of 
which 60% was either cured or biochemically controlled) with healthy individuals 7. They found 
that cognitive dysfunction, particularly attentional deficits, were common in acromegaly. Al- 
though this finding is of importance, again comparisons were made with healthy controls. More 
informative would be a comparison with patients who have nonfunctioning pituitary adenomas 
(NFA). These patients share many disease characteristics but do not have the GH excess. This type 
of study was performed by Tiemensma et al. 8, who concluded that there was normal cognitive 
functioning after long-term cure for acromegaly. The relation of previous GH excess with impaired 
cognitive functioning remains however controversial due to these inconsistent study results.
 In acromegaly, GH and IGF-1 may be discordant on medication during persistent disease. 
Biermasz et al. 9 demonstrated that octreotide did not lead to orderly GH secretion in acromegaly 
in spite of normalization of IGF-1. Neggers et al. 10 postulated that long-acting somatostatin ana-
logues normalize serum IGF-1 levels in certain patients in the presence of elevated GH actions in 
extrahepatic tissues. This phenomenon was called extrahepatic acromegaly. This change in diur-
nal GH profile, while IGF-1 is normalized, potentially also influences cognitive functioning. Until 
now no research is available on the effects of medical treatment in acromegaly on cognition.
 With these considerations in mind, we studied acromegaly patients with persistent disease 
(i.e. on GH suppressive mediation) and compared them with acromegaly patients who were in 





In this cross-sectional study, patients were recruited for participation at the endocrine outpatient 
clinic of the University Medical Center Groningen (UMCG), a tertiary referral center for pituitary 
surgery in the Netherlands. Inclusion criteria were as follows: age ≥ 18 years, treatment for acro-
megaly or NFA and regular follow-up in our endocrine outpatient clinic (i.e. at least once a year). 
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Additional in- and exclusion criteria, details of the study protocol and definitions of hormone de-
ficiencies are described elsewhere 11. Briefly, NFA and acromegaly patients were tested between 
September 2008 and November 2011. The diagnosis of NFA was based on two criteria: presence 
of a pituitary macroadenoma (>1 cm) on magnetic resonance imaging and absence of overpro-
duction of any of the pituitary hormones. The selection of the NFA patients was based on the 
absence of GH substitution, IGF-1 Z-scores within the age-adjusted normal range (> - 2) and zero 
or one axis being substituted. Pituitary deficiencies were defined according to generally accepted 
guidelines. The initial diagnosis of acromegaly was based on the characteristic clinical signs and 
symptoms and confirmed by insufficient suppression of GH during an oral glucose tolerance test 
(oGTT), elevated age-adjusted IGF-1 concentrations and the presence of a pituitary adenoma 
on radiologic imaging. Of the acromegaly patients who were included in this study, 28 were in 
remission (i.e. they had IGF-1 levels in the normal range, and a normal suppression of GH on oGTT 
(< 1.0 μg/L)), while 22 had persistent disease and were still treated with long-acting somatostatin 
analogues and/or pegvisomant. The consecutive approach to our acromegaly study patients was 
considered to be representative for the patient group, as published previously for NFA patients 12.
 
IGF-1 assay
Plasma IGF-1 was measured by radioimmunoassay after acid-ethanol extraction (Nichols Institute 
of Diagnostics, San-Juan Capistrano, CA, USA) 13. IGF-1 was measured on the day of testing. Data 
are reported as IGF-1 Z-scores.
 
Cognitive tests
Aspects of verbal memory were assessed with the 15 Words Test (15 WT) which is a Dutch equiv- 
alent of the Rey Auditory Verbal Learning Test 14. In this test, 15 words were presented five times. 
After each trial, patients were asked to name immediately the words they remembered. This 
allowed the calculation of three different scores describing immediate memory:
1. The short-term memory score is based on the number of words patients were able to name after 
the first presentation of the word list.
2. The total memory score represents the total number of words patients remembered over the 
five trials.
3. The learning score describes the difference between the number of words remembered in the 
third trial in comparison with the first trial.
Besides immediate memory, delayed memory was measured.
4. The delayed memory score is based on the number of words patients could recall after a period 
of about 30 minutes.
 Executive functioning was assessed using the Ruff Figural Fluency Test (RFFT) 15. In this test, 
patients were presented with sheets of paper on which 35 squares were printed, each with a fixed 
pattern of five dots. The test consisted of five parts, which differed with regard to the designs. 
While the configurations of dots are the same in the first three parts of the test, two types of 
distractions are added in two of these parts. In the last two parts, the configurations of the dots 
are different and without distractions. The participant was asked to produce as many different 
designs as possible by connecting two or more dots in each square with straight lines. The time 
for each part was restricted to 1 minute so that the total test time was 5 minutes. Responses 
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were scored with regard to the total number of unique designs generated over the five parts. The 
perseverative errors score represents the total number of repetitions of the same design drawn. The 
interrater variability (two independent raters) was determined by Pearson’s r and was 0.99 for 
both total unique designs and perseverative errors. The error ratio is the total number of persev-
erative errors divided by the total number of unique designs.
 
Questionnaires and protocol
A common questionnaire on demographic and health-related data was used with special atten-
tion for educational level, social status, full-time/part-time employment, social security benefit, 
comorbidity, use of medicine, cardiovascular risk factors, traumatic brain injury and dementia. 
Education level was determined using a Dutch education system, comparable to the ISCED 16. 
This scale ranges from 1 (elementary school not finished) to 7 (university level).
 The Hospital Anxiety and Depression Scale (HADS) was used to measure symptoms of anxiety 
and depression and consists of 14 items 17. Each item is scored as a number, with a maximum 
score for each subscale (anxiety or depression) of 21. Higher scores indicate more severe anxiety 
or depression.
 In fixed order, the test protocol was as follows: (1) the 15 WT: direct recall, (2) the RFFT, (3) a 
common questionnaire to assess baseline information, (4) physical examination: length, weight, 
blood pressure, waist circumference, hip circumference and compliance to the test situation, (5) 
the HADS and finally (6) the 15 WT: delayed recall.
 The assessment took approximately forty minutes and was performed directly after or just 
before patients’ visit to the outpatient clinic. All testing and scoring of tests were performed by 
trained personnel.
 
Reference data: healthy control subjects
The performances of patients were compared to Dutch controls. Normative data for the HADS 
were derived from Spinhoven et al 17. In this study, general population mean and standard devia-
tion scores were used from 18 to 65 years and >65 years to calculate Z-scores. Reference data for 
the 15 WT were derived from control subjects of the Maastricht Aging Study (n = 1780, aged 24 to 
81 years) 14. Regressions models given by the authors were used to determine accurate Z-scores. 
The final test scores were controlled for age, sex, and education. Reference data for the RFFT were 
derived from a sample (n = 10,289, half decades from 20 to 85 years) of the LifeLines Cohort Study 
18. Using the mean and standard deviation scores from this cohort, we standardized our patient 
scores by converting it into Z-scores.
 
Statistical analyses
The analyses were all carried out using the Predictive Analytics SoftWare (PASW; SPSS, Inc., 
Armonk, NY, USA) statistics 18 package. Demographic data are presented as median and inter-
quartile range (IQR), frequencies or percentages. Normality of data was analyzed by QQ-plots. 
Not all data were distributed normally; therefore, a nonparametric method was used to test for 
differences between the groups on the cognitive measures. Categorical variables were ana-
lyzed using Chi-square tests. Continuous variables were analyzed by the Kruskal-Wallis ANOVA. 
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Cognitive performance data were presented as median and IQR. A nonparametric 95% confi-
dence interval (CI) was calculated according to the method of Campbell and Gardner 19. Further-
more, an impaired performance was defined as a score ≤ 1.3 SD below the normative mean. Only 
10% of the overall normal population would be expected to score in this range 20. We compared 
three groups: acromegaly patients with persistent disease, acromegaly patients in remission and 
NFA patients. The two-tailed alpha level of <0.05 was considered statistically significant. In case 
of statistical differences between the groups on demographic or cognitive data, a Bonferroni cor-
rection was performed to protect against Type I error when performing multiple comparisons. In 
case of statistical differences between the groups on demographic or cognitive data, Duncan’s 
method was used as a post-hoc test 21.
 Reporting of the study conforms to STROBE statement along with references to STROBE state-




Seventy-four patients participated in the present study (35 men, 39 women, aged 57 ± 12 years, 
range 22-81 years). Fifty patients with acromegaly and 24 patients with NFA participated. The 
acromegaly patient group consisted of 22 patients with a persistent disease and 28 patients who 
were in remission. Patients’ characteristics are given in Table 1. The acromegaly patient groups 
were significantly younger at surgery, radiotherapy and time of testing compared with the NFA 
patient group. Acromegaly patients with persistent disease activity received significantly more 
often radiotherapy compared with acromegaly patients who were in remission and NFA patients. 
Furthermore, time since radiotherapy was longer in acromegaly patients who were in remission 
compared with acromegaly patients with persistent disease activity and NFA patients. The IGF-
1 Z-scores were comparable between both acromegaly groups and significantly higher com- 
pared with the NFA patient group, despite highly similar hormonal replacements. Both acromeg- 
aly patient groups had significantly higher anxiety Z-scores (indicating more anxiety) in com- 
parison with the NFA patient group, although there was no indication for clinical anxiety (Z-scores 




Table 1 Clinical characteristics of acromegaly patients with persistent disease, acromegaly patients in 






    
    
    
    
    
    
    






    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    























   
    
    
    
    
   
   
   
   
   
   
   
   












    
    
    
    
    
    
    
    























































































































































































































































































































































































































































































































































































































































































































































































































































































Cognitive performance data of the three groups are given in Table 2. The 95% CIs fall below zero 
for all memory scores and for the unique designs of the executive functioning test. For the same 
variables, a higher proportion of patients scored in the impaired range (all P < 0.001).
 Z-scores for cognitive functioning in acromegaly patients with persistent disease, acromegaly 
patients in remission and matched NFA patients are given in Table 3. No significant differences 
were found in median (IQR) cognitive Z-scores between the three groups.
 
Table 2. Cognitive performance of the total patient group 
Table 3. Cognitive performance of acromegaly patients with persistent disease, acromegaly patients in 
remission and NFA patients  
 
                 
  Table 3. Cognitive performance of acromegaly patients with persistent disease, acromegaly patients in 
remission and NFA patients 
     Acromegaly  NFA  P-value   
     Persistent disease  Patients in 
remission    
  
    N = 22 N = 28 N = 24 
 
        
 
  
  Memory performance       
  15 Words Test        
 Short-term memory  -0.74 [-1.69; 0.18] -0.28 [-0.89; 0.28] -0.28 [-1.17; 0.61] 0.274  
  Total memory  -0.85 [-1.63; 0.23] -0.90 [-1.53; -0.10] -0.55 [-1.75; 0.60] 0.557   
  Learning score  -0.03 [-0.65; 1.14] -0.63 [-1.60; 0.36] -0.67 [-1.12; 0.48] 0.088   
  Delayed memory   -0.55 [-1.83; 0.28] -0.90 [-1.93; -0.10] 0.65 [-1.55; 0.08] 0.714   
  Executive functioning       
  Ruff Figural Fluency Test       
  Unique designs  -0.83 [-1.51; 0.00] -0.29 [-1.42; 0.74] -0.62 [-1.61; 0.15] 0.538   
  Perseverative errors 1.05 [-0.32; 1.35] 1.04 [0.04; 1.31] 0.92 [0.26; 1.26] 0.926   
  Error ratio 0.56 [-0.90; 1.22] 0.80 [0.28; 1.13] 0.67 [0.22; 1.12] 0.691   
Cognitive performance data are given as z-scores median [Interquartile range].  




CI, Confidence interval; IQR, interquartile range 
*P-values by chi-square test comparing the number of patients who score in the impaired range  
to the number of patients who scored in the unimpaired range. 
Table 2. Cognitive performance of the total patient group   
   Median [IQR] 95% CI of the 
median 
Score ≤ 10 perc. 
           n 
  P-value*   
  Memory performance      
  15 words test      
  Short-term memory -0.36 [-1.29; 0.45] -0.61; -0.07 18 <0.001  
 Total memory -0.80 [-1.60; 0.33] -1.00; -0.40 24 <0.001  
 Learning score  -0.51 [-1.28; 0.53] -0.74; -0.03 18 <0.001  
  Delayed memory -0.80 [-1.73; 0.03] -1.20; -0.30 27 <0.001  
  Executive functioning     
  Ruff Figural Fluency Test    
  Unique designs -0.52 [-1.51; 0.21] -0.94; -0.10 22 <0.001  
  Perseverative errors 1.02 [0.04; 1.27] 0.76; 1.17 5 0.778  




In the present study, we found no association between previous GH excess and cognition. In 
addition, current medical treatment for GH excess was not related to impairments in memory 
and executive functioning. Although no differences were found between patient groups, most 
test results differed significantly from the reference populations, indicating a poor cognitive test 
performance in both patients with acromegaly and NFA.
 Only a few studies have addressed cognition in acromegaly. Sievers et al. studied 55 patients 
with biochemically confirmed acromegaly and compared their data with 87 control subjects. 
These patients were tested for attention, memory and executive functioning. They found that 
33% of the patients had an impaired score (< 16th percentile) in the domain of attention, 24% 
in the domain of memory and up to 17% in the executive functioning domain. However, no as-
sociations between the patient’s performance and their status of biochemical control, the current 
therapeutic regime, or the estimated total time of hormone excess, were found 7. With our more 
stringent cut-off values (≤ 10th percentile), we also found a high proportion of patients (72%) 
scoring in the impaired range on at least one outcome variable independent of their status of bio-
chemical control and the current therapeutic regimen. In a study by Leon-Carrion, moderate to 
severe memory impairment was found in acromegaly patients compared with healthy controls 
with decreased neural activity in specific brain areas on quantitative electroencephalogram 5. A 
different approach to demonstrate altered cognitive function was applied by Tanriverdi et al. 23. In 
electrophysiological studies they used the P300 amplitude, which is related to updating of work- 
ing memory (decision making and memory processing), and found that the mean amplitude at 
all electrode sites was significantly lower in 18 patients with acromegaly when compared with 16 
healthy controls and GH deficient patients. However, the acromegaly patients were enrolled into 
the study before any medical and surgical intervention. Further, as the authors already acknowl- 
edged themselves, the skull thickness may have interfered in the measurements of the P300 
amplitudes in acromegaly patients.
 We decided to compare patients with biochemical control of acromegaly to patients with a 
pituitary disease but without previous hormone excess. In accordance with the present findings, 
Tiemensma et al. found that cognitive function in patients cured from acromegaly did not differ 
from patients treated for NFA. Intriguingly and in contrast to a bulk of evidence indicating that any 
disease (treatment) with its long-term effects results in impairment of cognitive functioning, they 
found no differences with matched controls 8.
 In our study, all but one of the participating patients had normal IGF-1 Z-scores. In spite of 
this metabolic control, acromegaly patients with persistent disease who are on medication are 
reported to have a disorderly GH secretion with repressed secretory burst-mass and non-pulsatile 
secretion on octreotide 9. Another form of discordance is also described between GH and IGF-1 
in patients with acromegaly. Neggers et al. 10 postulate that long-acting somatostatin analogues 
normalize serum IGF-1 levels in certain patients in the presence of elevated GH actions in extrahe-
patic tissues. For these reasons, it is very interesting to study the effects of medication in patients 
with persistent disease and compare them with acromegaly patients in remission. Previously, we 
demonstrated that quality of life is impaired in association with the need for prolonged postoper- 
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ative therapy by somatostatin analogues in patients with acromegaly 24. With regard to cogni-
tion, Sonino found no significant improvements in cognition after treatment with octreotide 25 
while others found improved cognitive functions 26. However, both studies assessed self-reported 
cognition which is known to be often unrelated to objective measures of cognition 27-29. Further, 
within person comparisons were made during active disease and controlled disease, indicating 
that the effects may not per se be related to GH and IGF-1 concentrations. We found no differ- 
ences between patients with persistent disease and patients who were in remission in spite of 
far more extensive treatment in persistent disease. This finding suggests that disease control by 
normalization of IGF-1 alone might be sufficient for improvements in cognitive functioning. This 
interpretation however remains to be confirmed because our study is cross-sectional in design 
and therefore limited to infer causality. Additional studies should take GH secretory profiles in 
these patients into account.
 Some limitations need to be addressed. First, we did not use an extensive battery of cognitive 
tests as is common in many studies on cognitive functioning. We specifically chose for this design 
to avoid multiple comparisons and thereby potentially inducing type 1 errors. It allowed us also 
to test a larger group than generally reported in the literature, thereby enhancing our statistical 
power. However, for future studies an extensive neuropsychological test battery is recommend- 
ed, where multiple cognitive domains are evaluated. Secondly, baseline and treatment charac-
teristics were at some points different between groups. Although this is an inherent weakness of 
all observational studies, potential effects have to be taken into account. Previously, we found no 
negative effects of radiotherapy on quality of life and cognition 11-13. In regression analysis, we also 
found no effects of radiotherapy (data not shown).
 In conclusion, we found no effects of previous GH excess on cognition. Additionally, acromeg- 
aly patients on GH suppressive medication with normal IGF-1 Z-scores performed similarly to acro-
megaly patients who were in remission and NFA patients despite potential differences in diurnal 
GH concentrations. Based on these findings, the endocrinologist can inform acromegaly patients 
that memory and executive functioning are not expected to change as a consequence of the GH 
excess in history or the GH suppressive medication. However, patient groups had poorer cogni-
tive performance corrected for age, and educational level than the reference population, indi- 
cating that other disease related factors may potentially be important for cognition. Therefore, 
more research is needed in the field of cognition in patients with hormonal deficits.
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Cognition and adrenal insufficiency
Abstract
 
Background Extensive evidence in healthy volunteers links cognition to plasma glucocorticoid 
levels. However, no studies have been performed in patients with secondary adrenal insufficiency 
(SAI) on replacement doses with hydrocortisone aiming to mimic normal physiology. The present 
study focused on the effects of SAI on cognition by applying a comprehensive cognitive test bat-
tery consisting of tests measuring various aspects of memory, attention, executive functioning as 
well as social cognition.
 
Methods Sixty patients with SAI participated in the present study (35 men and 25 women, 
mean(SD) age 52(14) years, range 19-73). Patients were treated with hydrocortisone at the time of 
assessment (mean(SD) dose, 25(5) mg hydrocortisone). Patients’ performances on standardized 
cognitive tests were compared to age-, sex- and education-matched normative data collected on 
the healthy population.
 
Results Data analysis revealed significant impairments of patients in the domains of verbal mem- 
ory, attention, executive functions and social cognition, while no dysfunctions were found with 
regard to visual memory. Various treatment modalities and treatment related characteristics were 
related to impairments in different cognitive domains.
 
Discussion The cognitive profile indicates that pituitary patients treated for adrenal insufficien-
cy do not show a general cognitive impairment but rather a pattern of selective deficits with 
some cognitive domains being impaired while others remain preserved. In addition, treatment of 







Patients with secondary adrenal insufficiency (SAI) have impaired adrenocorticotropic hormone 
(ACTH) production and are treated with glucocorticoids (GC) to compensate for the loss of en-
dogenous cortisol production. Usually this is done by oral administration of hydrocortisone (HC) 
or cortisone acetate (CA) aiming to mimic a normal circadian cortisol rhythm, with peak values in 
the early morning and low concentrations at bedtime.
 GC substitution therapy, despite being referred to as a physiological replacement of GC, has its 
imperfections. Current GC dose-regimens inevitably result in over- or under-replacement during 
certain periods of the day. This may reduce quality of life and lead to higher risks of mortality and 
morbidity in patients with hypopituitarism compared to the normal population 1,2.
 Besides a poor quality of life and physical side effects, cognitive side effects have also been 
reported in healthy individuals treated with GC. There is compelling evidence of an inverted “U”-
shape relation between plasma GC levels and cognitive function 3. In particular, deficits in mem- 
ory 4-11  and executive functioning 12, 13 are reported in association with higher cortisol doses in 
healthy volunteers. These impairments could be explained by the fact that memory and ex- 
ecutive functioning rely on brain structures containing high concentrations of GC receptors, like 
the hippocampus 14 and the prefrontal cortex 15. Indeed, chronically elevated cortisol levels are 
associated with a reduced hippocampal volume and impairments in memory 8. The prefrontal 
cortex is, however, not only associated with executive functioning, but also with social cognition 
16 and attention 17.
 To our knowledge there are no studies examining the effects of long-term HC replacement on 
cognition in patients with SAI. Therefore, the aim of this study was to examine cognitive function- 





In this cross-sectional study, patients were recruited for participation at the endocrine outpatient 
clinic of the University Medical Center Groningen (UMCG), a tertiary referral center for patients 
with pituitary diseases in the Netherlands. A total of 60 patients participated in this study. All 
patients had SAI for which they received GC substitution therapy. To avoid effects of different 
types of GC, all patients on CA were converted to treatment with HC in a bioequivalent dose, 
(i.e. CA dose (in mg) times 0.8 when compared to HC dose (mg)) during a four week run-in phase. 
The diagnosis of SAI was based on internationally accepted biochemical criteria, principally early 
morning (08.00 – 09.00 am) serum cortisol measurements and if necessary an insulin tolerance 
test. Early morning cut off cortisol levels for adrenal insufficiency in our center were validated 
for patients with hypothalamic-pituitary disorders as previously published 18. Thyroid hormone 
deficiency was based on a low serum free thyroxine concentration (<11.0 pmol/l). Growth hor-
mone deficiency was based on a low insulin-like growth factor 1 (IGF-1) Z-score (less than 2 SD) 
and/or an insufficient peak growth hormone (GH) concentration (<10 mU/l) in response to in-
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sulin-induced hypoglycaemia or a peak growth hormone <18 mU/l during an arginine-GHRH 
test (<18 mU/l). Insufficiency of the pituitary– gonadal axis was defined in men as a testosterone 
concentration below 10 nmol/l, in premenopausal women (aged <50 years) as loss of menses 
and in postmenopausal women (aged >50 years) as LH and FSH concentrations below 15 mU/l. 
Diabetes insipidus was defined as the incapacity to properly concentrate urine (increased urine 
volume with low urine osmolality) in the face of a high plasma osmolality (and sodium). Biochem- 
ical control of adequacy of hormonal substitution treatment was judged by the physicians that 
were responsible for the care of the participating patients using free thyroxine, insulin-like growth 
factor 1 and testosterone levels where necessary. Other inclusion criteria were age 18 - 75 years, 
time interval of at least one year between study entry and tumor treatment with surgery and/or 
radiotherapy and adequate replacement of all other pituitary hormone deficiencies for at least six 
months prior to entry of the study.
 Main exclusion criteria were documented severe cognitive impairment (MMSE < 24) 19, drug 
abuse or dependence, current psychiatric disorders, previous Cushing’s disease, diabetes mellitus 
with medication known to be able to induce hypoglycemia (e.g. Sulfonylurea derivatives and 
insulin) and a history of frequent episodes of clinical hypocortisolism. Concomitant drugs known 
to interfere with HC metabolism, e.g. antiepileptics, were also not allowed 20.
 All patients were tested in the period between May 2012 and January 2013. The baseline 
characteristics of the entire cohort of patients with SAI (n=135) did not differ from the presented 
study population, confirming the representativeness of our study population (data not shown).
 
Ethics Statement
The study protocol was approved by the local ethics committee at the UMCG, The Netherlands. 
Participants gave written informed consent before entering the study.
 
Cognitive tests
A battery of 11 standardized cognitive tests which resulted in 37 test scores covering 4 cognitive 
domains (memory, attention, executive functioning and social cognition) was used. This battery 
included: the Rivermead Behavioral Memory Test (RBMT), the 15 Words Test, Digit Span test, Rey 
Complex Figure test, the Test of Attentional Performance, verbal fluency tests, the Trail Making 




A common questionnaire on demographic and health-related data was used to assess educa-
tional level, social status, full-time/part-time employment, social security benefit and use of med- 
ication. Educational level was classified using a Dutch education system, comparable to the 
International Standard Classification of Education (ISCED) 21. This scale ranges from 1 (elementary 
school not finished) to 7 (university level).
 
Procedure
The cognitive test battery took approximately 3 hours including a coffee break. All testing and 
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scoring of tests was performed by trained personnel under the supervision of two neuropsychol- 
ogists (PB and JK).
 
Statistical analyses
All statistical analyses were performed using Statistical Package for the Social Sciences (SPSS, Inc., 
Armonk, NY, USA), version 20. Demographic data are presented as median, interquartile ranges 
(IQR), frequencies or percentages. Normality of data was analyzed using Q-Q plots. Since not all 
data were normally distributed, patients’ cognitive performances were compared to the reference 
group by using non-parametric tests. Cognitive performance data were presented as mean Z-
score with a non-parametric 95% confidence interval (CI) 22. To analyze the influence of treatment 
characteristics, patients with at least one impaired score per cognitive domain (memory, atten-
tion, executive functioning and social cognition) were compared to patients with no impairments 
in the same domain in a univariate model. This model consisted of the variables: surgery, age at 
surgery, time since surgery, radiotherapy, age at radiotherapy, time since radiotherapy, dosis HC, 
mg HC/kg body weight and the use of thyroid hormone, growth hormone, sex hormone and 
desmopressin substitution. The use of sex hormones in men and women was not evaluated sep- 
arately, since this would yield many different and small groups. A cognitive impairment on a test 
was defined as a performance equivalent to the performance of the lowest 10% of the reference 
samples 19. Comparisons were only performed if the size of the groups was sufficient (i.e. n > 5). 
Categorical variables were analyzed using chi-square tests. Continuous variables were analyzed 





Sixty patients with SAI participated in the present study (35 men and 25 women, mean (SD) age 
52(14) years, range 19-73). Patients’ characteristics are given in Table 1. Multiple pituitary insuf-
ficiencies were present in 57 patients (95%), while isolated ACTH deficiency was present in 3 
patients (5%). Thirty one patients were treated for a pituitary adenoma (19 patients with a non-
functioning macroadenoma, 6 patients with a macroprolactinoma, 6 patients with acromegaly). 
Five patients received treatment for a cyst with pituitary localization, 5 had a craniopharyngioma, 
7 had a tumor distant from the pituitary gland (including germinomas, meningeomas, ENT tu-
mor and a Primitive Neuroectodermal Tumor), and 5 patients had other acquired forms of ACTH 
deficiency (including Sheehan and traumatic brain injury). In addition, 7 had a congenital form 
of ACTH deficiency (6 combined, 1 isolated). Twenty-nine patients previously had undergone 
transsphenoidal surgery, 12 patients had undergone a craniotomy, 5 patients had primary radio-
therapy and 21 patients had adjuvant radiotherapy. The median [IQR] cumulative daily HC dose 
was 25 [20; 30] mg. When corrected for kg body weight the median [IQR] HC dose was 0.31 [0.25; 
0.35] mg. Most patients (70%) received twice daily dosing.
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Cognitive tests
Table 2 summarizes mean Z-scores with a 95% CI for all cognitive measures. Tables 3a-d show the 




Patients showed significantly lower scores on immediate, delayed and short-term verbal memory 
(RBMT and 15 words test). However, the mean delayed Z-score for the short story (RBMT) fell in the 
normal range when corrected for immediate memory. The performance on short-term memory 
(digit span forward) was significantly better compared to the reference sample. In addition, the 
non-verbal immediate and delayed memory scores of the Rey Complex Figure were significantly 
better compared to the reference sample. Of the entire patient sample, 80% (n=48) showed an 
impairment of at least one of the memory measures. Patients who received radiotherapy showed 




Reaction times of patients in response to auditory stimuli of the divided attention task were sig-
nificantly slower compared to reference data, whereas the reaction times of the visual stimuli 
fell in the normal range. During this task, patients made more omission errors compared to the 
reference sample. With regard to visual scanning, when patients had to press the key when a 
target stimuli was present, they reacted slower and had an increased variability in reaction times. 
When patients had to press the key when the target was not present, reaction times were faster 
although patients showed an increased variability of reaction time and also an increased number 
of commission errors. With regard to alertness, reaction times were significantly slower when 
patients had to respond as quickly as possible when a cross appeared (tonic alertness) and also 
when a warning tone preceded the appearance of the cross (phasic alertness). Of the entire sam-
ple, 85% (n=50) showed an impaired performance of at least one of the measures of attention. 
The time interval since surgery was significantly longer in impaired patients compared to unim-
paired patients. Furthermore, patients in the impaired group used thyroid hormones more often 




Patients scored significantly worse on divergent thinking (fluency test) when they had to gener- 
ate as many words as possible given a category (semantic fluency), but not when patients had to 
start with a specific letter (phonemic fluency). Assessment of psychomotor speed and cognitive 
flexibility (Trail Making Test, condition A and B) revealed that patients were significantly slower 
during both condition A and condition B. However, when the performance on condition B (cog-
nitive flexibility) was corrected for the influence of condition A (psychomotor speed) the patient 
group and the reference sample did not differ anymore. Of the entire patient sample, 43% (n=26) 




Patients showed a significantly reduced performance on the recognition of emotions of the eye 
region as shown in pictures (the Reading the Mind in the Eyes Test) compared to the reference sam-
ple. In total 37% (n=22) showed an impairment in this domain. Time since radiotherapy was signifi-
cantly longer in the impaired patient group compared to the unimpaired patients (Table 3d).
 
Table 1. Clinical characteristics of pituitary patients treated for adrenal insufficiency (N=60)Table 1. Clinical characteristics of pituitary patients treated for adrenal insufficiency  
(N=60) 
  
Basic characteristics   
Age (y), median [IQR]  55 [46; 62] 
Sex (males/females) 35/25 
Educational level (1/2/3/4/5/6/7) ♦ (0/2/1/9/28/18/2) 
Age at diagnosis (y), median [IQR] 34 [21; 47] 
Childhood onset/Adult onset of SAI 8/52 
Surgery (n = 41)  
Transsphenoidal surgery/ Craniotomy (%) 71/29 
Age at surgery (y), median [IQR] 40.8 [24.5; 50.5] 
Average time since surgery (y), median [IQR] 11.4 [6.7; 21.0] 
Patients with 2nd surgery (%)  13.3 
Radiotherapy (n = 26)  
Pituitary radiotherapy/cranial irradiation/ 
radiotherapy for extracranial tumors (%) 
77/19/4 
Age at radiotherapy (y), median [IQR] 37.5 [23.6; 48.4] 
Average time since radiotherapy (y), median [IQR]  14.6 [10.5; 24.8] 
Hydrocortisone Treatment   
Total daily dose (mg/day), median [IQR] 25 [20; 30] 
Dose/kg body weight (mg/kg), median [IQR] 0.31 [0.25; 0.35] 
Number of daily dosings (1/2/3) (%) 5/70/25 
Duration of hydrocortisone treatment (y), median 
[IQR] 
11.4 [5.4; 21.9] 
 
No. of hormonal replacements (1/2/3/4/5) 3/12/25/17/3 
Thyroid hormone (% of  patients substituted)  92 
Growth hormone (% of  patients substituted) 50 
Growth hormone deficiency (% of patients 
unsubstituted) 
33 
Sex hormone (% of patients substituted) 
Men: testosterone (% of  patients substituted) 
Premenopausal women, n=10: estrogens (% of  
patients substituted) 






Desmopressin (% of  patients substituted) 22 
♦ Educational level was classified using a Dutch education system, comparable to  
the International Standard Classification of Education (ISCED) (21). This scale  
ranges from 1 (elementary school not finished) to 7 (university level).  
IQR: Interquartile range, SAI: Secondary adrenal insufficiency, NA: Not applicable.   
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Table 2. Cognitive performance of pituitary patients treated for adrenal insufficiency (N=60)
Table 2. Cognitive performance of pituitary patients treated for  adrenal insufficiency (N=60) 
 Mean Z-score [95%CI]   P-value* 
Memory   
RBMT†   
Immediate memory -0.79 [-1.05; -0.53] <0.001 
Delayed memory -0.72 [-0.96; -0.48] <0.001 
Delayed corrected for immediate memory -0.09 [-0.44; 0.26] 0.624 
15 Words Test†   
Short-term memory -0.31 [-0.57; -0.05] 0.017 
Total immediate memory -0.51 [-0.77; -0.25] <0.001 
Learning score 0.09 [-0.18; 0.36] 0.490 
Delayed memory -0.50 [-0.77; -0.23] <0.001 
Delayed corrected for total memory -0.24 [-0.46; -0.02] 0.032 
Recognition -0.17 [-0.38; 0.04] 0.121 
Digit Span forward†   
Short-term memory 0.27 [0.03; 0.51] 0.025 
Rey Complex Figure ‡   
Immediate memory 0.66 [0.31; 1.02] <0.001Δ 
Delayed recall 0.60 [0.25; 0.95] <0.001Δ 
Attention   
Divided attention‡   
Reaction time auditory responses  -1.02 [-1.24; -0.80] <0.001 
Variability of reaction time auditory 
responses 
0.09 [-0.18; 0.36] 0.490 
Reaction time visual responses -0.20 [-0.45; 0.05] 0.123 
Variability of reaction time visual 
responses 
-0.21 [-0.49; 0.07] 0.158 
Number of omission errors -0.51 [-0.75; -0.27] <0.001 
Number of commission errors 0.11 [-0.13; 0.35] 0.366 
Visual scanning‡  
Reaction time for target stimuli -0.74 [-0.97; -0.51] <0.001 
Variability of reaction time for target 
stimuli 
-0.69 [-0.91; -0.46] <0.001 
Number of omission errors -0.25 [-0.54; 0.04] 0.096 
Reaction time for non-target stimuli 0.82 [0.59; 1.05] <0.001 
Variability of reaction time for non-target 
stimuli 
-0.80 [-1.02; -0.58] <0.001 
Number of commission errors -0.74 [-0.82; -0.66] <0.001 
Alertness‡  
Tonic alertness reaction time -0.80 [-1.04; -0.56] <0.001 
Tonic alertness variablity in reaction time -0.10 [ -0.33; 0.13] 0.406 
Phasic alertness reaction time -1.07 [-1.25; -0.90] <0.001 




Executive functioning  
Fluency test†   
 Semantic fluency -0.24 [-0.47; -0.01] 0.041 
 Phonemic fluency -0.03 [-0.20; 0.14] 0.842 
Digit Span backwards†   
Working memory  0.19 [-0.07; 0.45] 0.139 
Trail Making Test‡   
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Variability of reaction time auditory 
responses 
0.09 [-0.18; 0.36] 0.490 
Reaction time visual responses -0.20 [-0.45; 0.05] 0.123 
Variability of reaction time visual 
responses 
-0.21 [-0.49; 0.07] 0.158 
Number of omission errors -0.51 [-0.75; -0.27] <0.001 
Number of commission errors 0.11 [-0.13; 0.35] 0.366 
Visual scanning‡  
Reaction time for target stimuli -0.74 [-0.97; -0.51] <0.001 
Variability of reaction time for target 
stimuli 
-0.69 [-0.91; -0.46] <0.001 
Number of omission errors -0.25 [-0.54; 0.04] 0.096 
Reaction time for non-target stimuli 0.82 [0.59; 1.05] <0.001 
Variability of reaction time for non-target 
stimuli 
-0.80 [-1.02; -0.58] <0.001 
Number of commission errors -0.74 [-0.82; -0.66] <0.001 
Alertness‡  
Tonic alertness reaction time -0.80 [-1.04; -0.56] <0.001 
Tonic alertness variablity in reaction time -0.10 [ -0.33; 0.13] 0.406 
Phasic alertness reaction time -1.07 [-1.25; -0.90] <0.001 




Executive functioning  
Fluency test†   
 Semantic fluency -0.24 [-0.47; -0.01] 0.041 
 Phonemic fluency -0.03 [-0.20; 0.14] 0.842 
Digit Span backwards†   
Working memory  0.19 [-0.07; 0.45] 0.139 
Trail Making Test‡   
Table 2. Cognitive performance of pituitary patients treated for  adrenal insufficiency (N=60) 
 Mean Z-score [95%CI]   P-value* 
Memory   
RBMT†   
Immediate memory -0.79 [-1.05; -0.53] <0.001 
Delayed memory -0.72 [-0.96; -0.48] <0.001 
Delayed corrected for immediate memory -0.09 [-0.44; 0.26] 0.624 
15 Words Test†   
Short-term memory -0.31 [-0.57; -0.05] 0.017 
Total immediate memory -0.51 [-0.77; -0.25] <0.001 
Learning score 0.09 [-0.18; 0.36] 0.490 
Delayed memory -0.50 [-0.77; -0.23] <0.001 
Delayed corrected for total memory -0.24 [-0.46; -0.02] 0.032 
Recognition -0.17 [-0.38; 0.04] 0.121 
Digit Span forward†   
Short-term memory 0.27 [0.03; 0.51] 0.025 
Rey Complex Figure ‡   
Immediate memory 0.66 [0.31; 1.02] <0.001Δ 
Delayed recall 0.60 [0.25; 0.95] <0.001Δ 
Attention   
Divided attention‡   
Reaction time auditory responses  -1.02 [-1.24; -0.80] <0.001 
Variability of reaction time auditory 
responses 
0.09 [-0.18; 0.36] 0.490 
Reaction time visual responses -0.20 [-0.45; 0.05] 0.123 
Variability of reaction time visual 
responses 
-0.21 [-0.49; 0.07] 0.158 
Number of omission errors -0.51 [-0.75; -0.27] <0.001 
Number of commission errors 0.11 [-0.13; 0.35] 0.366 
Visual scanning‡  
Reaction time for target stimuli -0.74 [-0.97; -0.51] <0.001 
Variability of reaction time for target 
stimuli 
-0.69 [-0.91; -0.46] <0.001 
Number of omission errors -0.25 [-0.54; 0.04] 0.096 
Reaction time for non-target stimuli 0.82 [0.59; 1.05] <0.001 
Variability of reaction time for non-target 
stimuli 
-0.80 [-1.02; -0.58] <0.001 
Number of commission errors -0.74 [-0.82; -0.66] <0.001 
Alertness‡  
Tonic alertness reaction time -0.80 [-1.04; -0.56] <0.001 
Tonic alertness variablity in reaction time -0.10 [ -0.33; 0.13] 0.406 
Phasic alertness reaction time -1.07 [-1.25; -0.90] <0.001 




Executive functioning  
Fluency test†   
 Semantic fluency -0.24 [-0.47; -0.01] 0.041 
 Phonemic fluency -0.03 [-0.20; 0.14] 0.842 
Digit Span backwards†   
Working memory  0.19 [-0.07; 0.45] 0.139 











Condition A, time 





Condition B, time -0.43 [-0.68; -0.18] <0.001 
Condition B, no. of corrections (0/1/2/3) 46/6/6/2  
Condition B/A -0.12 [-0.36; 0.12] 0.327 
Social cognition †‡   
Reading the Mind in the Eyes Test -0.94 [-1.21; -0.67] <0.001 
Comparing patients’ performance to reference data; †: verbal test; ‡: non-verbal test; CI: 
Confidence Interval; RBMT: Rivermead Behavioral Memory Test; ΔScores for n = 56 patients (4 
patients were excluded from analysis because of an impaired copy drawing, <10th percentile) 
(See Appendix) 
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Cognition and adrenal insufficiency
Discussion
This study demonstrated that patients treated for SAI showed impairments in the cognitive do-
mains of memory, attention, executive functions and social cognition compared to reference data 
of the general population. There is, however, a pattern of selective deficits that can be detect- 
ed with some cognitive functions being impaired while others remain preserved. Furthermore, 
we found that various forms of treatment in this patient population related to impairments in 
different cognitive domains.
 From previous studies in healthy volunteers, it is known that GC can impair aspects of cogni-
tion that depend upon the integrity of the hippocampus, i.e. declarative memory (memory we 
have conscious access to) 23. These results are confirmed by the present study which shows that 
80% of SAI patients display an impairment on at least one memory test. The present study goes, 
however, beyond previous findings and demonstrates a discrepancy between verbal and non-
verbal declarative memory in patients with SAI. With regard to verbal memory it was found that in 
particular the encoding and retrieval of information is impaired, with the impairment of retrieval 
being specific for incoherent information compared to coherent information. The recognition 
of verbal information appears to be unimpaired, most likely because this task requires only the 
relatively simple decision as to whether specific information was encountered before or not. The 
finding of an intact recognition while the encoding and retrieval of verbal information is affected, 
is in line with a study from de Quervain and colleagues 4.
 The patients with SAI in this study showed no impairments on the non-verbal memory tasks 
and performed even significantly better than the reference samples. One explanation for this 
might be that exogenous cortisol leads to more positive-going waveforms over the right than 
the left hemisphere, which are involved in non-verbal and verbal memory, respectively 11. Fur-
thermore, if verbal memory is more affected by exogenous cortisol than non-verbal memory, 
patients might have learned to cope with this by applying more visual compensation techniques. 
Another explanation for the better performance of the patient group in the non-verbal memory 
test compared to the reference sample could be that the patient group put more effort in this test 
compared to the reference group 24. No general memory deficit was thus found in the present 
study, indicating selective impairments which might at least in part be determined by the mate-
rial that has to be processed (verbal versus non-verbal and coherent versus incoherent).
 In the cognitive domain of attention, 85% of SAI patients showed an impairment. Patients 
displayed in particular a slower processing speed or increased reaction times on most tests. A 
discrepancy was, however, found for the divided attention task during which both auditory and 
visual stimuli need to be processed simultaneously. Patients showed significantly slower reaction 
times in response to the auditory stimuli but not in response to visual stimuli. Apparently, patients 
automatically pay more attention to visual stimuli compared to auditory stimuli, which is in ac-
cordance with the discrepancy observed between verbal and non-verbal (i.e. visual) memory. 
As suggested earlier, patients might have learned visual compensation techniques and uncon-
sciously pay more attention to visual stimuli. Furthermore, it was found that patients do not pay 
sufficient attention to relevant stimuli, i.e. they display a significantly higher number of omission 
errors (lack of response to target stimuli) during the divided attention task. In the selective atten-
 0 
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tion task, patients showed more commission errors (responses to non-target stimuli during the 
visual scanning task) which could be indicative of an increased impulsivity. Taken together, pa-
tients with SAI have a slower processing speed in addition to a potentially increased distractibility 
and impulsivity.
 With regard to executive functioning, selective deficits were also found on semantic fluency 
whereas phonemic fluency was unimpaired. This pattern was previously detected in patients with 
Parkinson’s disease 25,26. It has been suggested that even though both fluency measures depend 
on the integrity of executive functions, semantic fluency tests are also influenced by the integrity 
of semantic memory 25. The difference between semantic and phonemic fluency might therefore 
be (partly) explained by impairments in declarative memory which were also found in the present 
study. Other aspects of executive functioning, i.e. cognitive flexibility and working memory were 
not impaired compared to the reference data of the general population. However, when a more 
clinical individual approach was used the results show that 43% of patients treated for SAI have 
at least one impairment in the domain of executive functioning. Impairments in executive func-
tioning have previously been demonstrated in healthy participants receiving different doses of 
HC by infusion 12. The apparent discrepancy between no major average group effect on the one 
hand and the higher prevalence of at least one impairment for an individual patient on the other 
hand justifies a more personal approach for cognitive evaluation.
 Impaired performances were also found in the domain of social cognition. Social cognition 
refers to the mental operations that underlie social interactions, including the perception of emo-
tions, interpreting social behavior, and generating responses to the intentions, dispositions, and 
behaviors of others 27. An impaired performance in this domain was already found in women, 
with higher levels of cortisol leading to decreased performances on social cognition tasks 28. The 
current study found a decreased social cognitive performance in both men and women with 
SAI. Furthermore, when a more clinical approach was used, 37% of pituitary patients treated for 
adrenal insufficiency showed an impairment. Social cognition is, however, a complex cognitive 
function which was not examined in detail in the present study. Future studies should therefore 
put a bigger emphasis on the domain of social cognition in patients with SAI.
 Different treatment modalities and treatment related factors were associated to cognition 
in patients with SAI. In exploratory analyses, the use of thyroid hormone was more frequent in 
patients with impaired attention, whereas the use of desmopressin was borderline significantly 
associated with better memory performance. The association between thyroid hormone and 
cognition is in line with a recently published study by Beydoun et al. 29. The latter is consistent with 
the study of Vawter et al. who also found that a vasopressin fragment improved long-term and 
short-term memory, although this was found in rats 30. In addition, glucocorticoid dose correct- 
ed for body weight was higher in patients with impaired psychomotor speed (TMT-A, data not 
shown), a finding that warrants further investigation. Also, ten patients without growth hormone 
substitution (33%) had IGF-1 Z-scores < -2, indicating unsubstituted severe GH deficiency in this 
population. This is usually the consequence of an absence of GH deficiency related symptoms or 
lack of patient benefit on GH treatment. Untreated GH deficiency might also have influenced re-
sults 31-33. However, except for one outcome measure, the patients with IGF-1 Z-scores <-2 did not 
perform significantly different compared to patients with IGF-1 Z-scores within the normal range 
(i.e. patients with untreated GH deficiency scored significantly lower on the semantic fluency test, 
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data not shown). Both radiotherapy and surgery were found to be associated with poorer perfor-
mance on memory, executive functioning, attention and social cognition. In our previous studies 
34,35, we did not reveal such effects of radiotherapy and surgery when comparing the group of 
pituitary patients to reference data of the general population, also not on self reported cognition 36. 
This discrepancy might be explained by the different tests used to examine cognition in these stu-
dies. One could argue that a Bonferroni correction for multiple testing should have been perform- 
ed. However, although we performed multiple comparisons, the cognitive domains assessed in 
the current study are not fully dependent on each other. Furthermore, this was a hypothesis gen- 
erating analysis and not a hypothesis affirmative research. Therefore, we show absolute p values 
and demonstrate that different cognitive domains relate to different treatment characteristics. 
The implication of these findings is that certain treatments do not globally affect cognition but 
may rather result in selective impairments. This is a conclusion that does not depend on p values 
with a certain statistical cut-off , but rather on different overall patterns.
 To our knowledge, this is the first study on the effects of long-term physiological doses of HC 
in patients with SAI in relation to cognition as examined with a comprehensive cognitive battery 
consisting of psychometric tests. The results seem to be consistent with earlier findings indicat- 
ing an impaired cognitive performance in healthy subjects with altered glucocorticoid levels 4-7, 
9, 10, 12, 13. Some study limitations, however, need to be addressed. First, this is a cross-sectional 
study. Cross sectional studies are effective when evaluating a large group of patients and the 
associations with treatment characteristics. However, we cannot draw any conclusions about HC 
exposure and cognitive outcome, since exposure and outcome are determined at the same time. 
Secondly, a healthy control group was not included in the current study. Therefore it is not clear to 
what extent individuals in the general population are impaired on at least one test in the specific 
cognitive domains. However, the magnitude of differences in Z-scores as shown in Table 2 highly 
suggest that impairments on at least one test in a specific domain is not as prevalent as in our 
patient population. Future studies on cognition should include a control group, which consists of 
healthy individuals who are matched for age, sex and education to the group of patients. Thirdly, 
we have to bear in mind that the average daily dose of HC based on body weight of the patient 
group included in the present study is somewhat higher than is generally accepted as desirable 
37. However, as experienced in our own outpatient group, it can be difficult to change treatment 
strategies because patients are used to their treatment regimes for many years and other treat- 
ment regimens might cause undesirable symptoms (e.g. sleep disturbances and headache). 
Lastly, in this study patients with different surgery and radiotherapy techniques were examined. 
Although the aim of the study was to examine cognitive functioning in a representative group of 
patients with SAI as they are treated nowadays (i.e. with different treatment characteristics), one 
should be aware of the fact that different surgery and radiotherapy techniques might have dif-
ferent effects on cognition, potentially obscuring subtle effects.
 In conclusion, no global cognitive impairments were found in pituitary patients treated for 
adrenal insufficiency, but rather various selective deficits, in particular on verbal cognitive tasks, 
with some cognitive functions being impaired while others remaining preserved. The results of 
the present study are of importance for patient management, since cognitive impairments fre-
quently affect every day functioning.
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Appendix. Full description of cognitive tests and reference data
 
The following cognitive domains were assessed using several standardized and validated cogni-
tive tests: memory, attention, executive functioning and social cognition.
 
Memory
During the Rivermead Behavioral Memory Test (RBMT) 1, a short story was read out loud to pa-
tients who were then asked to immediately recall as many details as possible from the story. 
This allowed the calculation of an immediate memory score for coherent verbal information. A 
delayed memory score for coherent verbal memory was determined based on the number of 
details of the story recalled by patients after a period of about 30 minutes. Verbal memory was 
also assessed with the 15 Words Test, which is a Dutch equivalent of the Rey Auditory Verbal 
Learning Test 2. During this test, 15 words were presented five times. After each trial, patients 
were asked to name immediately the words they remembered. This allowed the calculation of 
three different scores describing immediate memory. The short-term memory score is based on 
the number of words patients were able to name after the first presentation of the word list. The 
total immediate memory score represents the total number of words the patients remembered 
over the five trials. The learning score describes the difference between the number of words 
remembered in the third trial in comparison with the first trial. Besides immediate memory, de-
layed memory was measured with the 15 Words Test. The delayed memory score is based on the 
number of words a patient could recall after a period of about 30 minutes. To correct for the total 
immediate memory, there was also a delayed corrected for total memory score. The last part of the 
test was a recognition task. A total of 30 words were presented to the patient, of which 15 words 
were presented during the previous five trials and of which 15 words were new to the patient. The 
patients had to decide whether the words were new or familiar, which allowed the calculation of 
a recognition memory score.
 To assess short-term memory, the Digit Span Forward test was used 3. Patients were presented 
with a sequence of digits and immediately had to repeat the digits in the same order as they were 
presented. The test started with sequences of two digits which expanded until the maximum of 
nine digits. When a patient could not correctly repeat two sequences of the same length, the test 
was aborted. The total number of correctly repeated sequences was registered. Visual memory 
was assessed with the Rey Complex Figure Test 4. During this test, a complex geometrical figure 
was placed in front of patients, who were instructed to copy the figure as accurately as possible. 
After a 3-minute delay, patients were asked to reproduce the figure from memory. Approximately 
15 minutes later, patients were again asked to reproduce the figure from memory. The number of 
details correctly recalled after 3 and 15 minutes were used to calculate an immediate and delayed 
memory score. If patients had an impaired copy drawing (<10th percentile) measures of imme-
diate and delayed memory were excluded for analysis. An impaired copy drawing might indicate 






The Test of Attentional Performance is a computerized test consisting of several subtests 5. In 
the present study, the subtests divided attention, visual scanning and alertness were used. Test 
instructions were presented on a computer screen and read out loud by the test examiner. In 
order to familiarize the participants with the tasks, a brief sequence of practice trials preceded 
each test.
 Divided attention is needed when two (or more) tasks have to be performed simultaneously. 
In the visual task, a series of matrices was presented in the center of the computer screen. Each 
matrix (4x4) consisted of a regular array of sixteen dots and crosses. When four of these crosses 
formed a square, patients had to press a key as quickly as possible. The acoustic task consisted 
of a high (2000 Hz) and low (1000 Hz) tone which were presented alternately according to the 
synchronous rhythm of the changing positions of the crosses. When the same tone occurred 
twice in a row, patients had to press a key as quickly as possible. A total of 100 visual and 200 
acoustic stimuli was presented including 17 visual and 16 acoustic targets. Reaction time of cor-
rect responses, variability in reaction time and the number of omission (lack of response to target 
stimuli) and commission (responses to non-target stimuli) errors were calculated and represented 
measures of divided attention.
 During the visual scanning task a series of 5 by 5 matrices were presented. Each matrix con-
sisted of a regular array of 25 squares which each had an opening on one side (top, bottom, left 
or right side). A square with an opening on the top was defined as the target stimulus. The target 
stimulus occurred in 50% of matrices and was randomly distributed across the matrix. Patients 
were asked to press the left response button as quickly as possible when a matrix contained the 
target stimulus and to press the right response button if the target stimulus was not present. A 
total of 50 trials was presented (25 target trials and 25 non-target trials). Reaction times of correct 
responses, variability of reaction time and the number of commission and omission errors were 
calculated and represented measures of selective attention, i.e. attention for the target stimulus 
and not for non-target stimulus.
 During the alertness task, reaction times were measured during two conditions. The first con-
dition concerned a simple reaction time measurement, during which a cross appeared on the 
screen at random varying intervals. Patients were instructed to respond as quickly as possible by 
pressing a key when the cross appeared (tonic alertness task). In the second condition, a warning 
tone preceded the appearance of the stimulus (phasic alertness task). A total of 40 trials were 
presented, 20 trials with warning tone and 20 trials without warning tone. The time span between 
the warning tone and the appearance of the stimulus was random (between 300 and 700 ms). 
Measures of tonic and phasic alertness were calculated on the basis of reaction times of patients. 
In addition, the variability of reaction time and the number of omission errors were measured.
 In this study, data of the Test of Attentional Performance were derived from 59 patients due to 
a technical problem with the computer during one patient visit.
 
Executive functioning
Divergent thinking is the ability to approach a task or situation in different ways. So-called flu-
ency tests rely on divergent thinking and evaluate the spontaneous production of words under 
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restricted search conditions 6. During the first fluency test applied in the present study, the se-
mantic subtest, patients were asked to name as many animals as possible within one minute. 
Participants were not allowed to name the same word twice. The total number of correctly pro-
duced animals was counted. In a second fluency test, the phonemic subtest, patients were asked 
to name as many words as possible in one minute, starting with a specific letter. All existing nouns 
were allowed. However, personal names and names of places were not allowed. This part was ad-
ministered three times, each time using a different letter, namely D, A and T 7.  For both subtests, 
the total number of correctly produced words was counted. To assess working memory, the Digit 
Span Backward test was used 3. Patients were presented with a sequences of digits, which they 
had to repeat backwards. The test started with sequences of two digits which expanded until the 
maximum of eight sequences. When a patient failed to correctly repeat two sequences of the 
same length, the test was aborted. The total number of sequences that was repeated correctly 
was registered.
The Trail Making Test assesses visual scanning, speed of processing (condition A), cognitive flexi-
bility (condition B) 8. During condition A, patients were asked to connect 25 circles containing 
numbers as quickly as possible in ascending order. Part B consisted of 25 circles, containing both 
numbers and letters. Patients were again required to connect the circles as fast as possible in as-
cending order, this time alternating between numbers and letters i.e. 1-A-2-B-3-C, etc.. The target 
measure for cognitive flexibility was the performance on condition B corrected for condition A 
(Trail Making Test B/A).
 
Social cognition
Social cognition can be defined as the mental operations that underlie social interactions, in-
cluding perceiving, interpreting, and generating responses to the intentions, dispositions, and 
behaviors of others 9. In this study, social cognition was assessed with the Reading the Mind in 
the Eyes Test (RMET) 10. During this test, patients were presented with 36 photographs, one after 
each other, of the eye-region of the face. Along with each pair of eyes, four words describing an 
emotion were presented. Patients were asked to choose which word described best what the 
person in the picture is feeling or thinking. To exclude any influence of difficulties with word com-
prehension, a glossary with the presented words was made available.
 
Reference data: Healthy control subjects




The results of the RBMT were compared to a healthy reference group (n=344) consisting of par-
ticipants aged 17-89 11. The scores of patients were corrected for age, sex and education. In the 
study by Schmand et al., participants were presented with two stories of comparable length. How- 
ever, in the present study, patients were presented with only one story. To compensate for this 
difference, the score obtained in the present study was doubled. Reference data for the 15 Words 
Test were derived from control subjects (n=847) consisting of participants aged 14-87 11 for the 
 0 
Chapter 6
measures total immediate memory, delayed memory and delayed corrected for total memory. 
Reference data for the measures short-term memory, learning score and recognition of the 15 
Words Test were derived from control subjects of the Maastricht Aging Study 2. The scores were 
corrected for age, sex and education. The results of the Digit Span test were compared to the 
reference group as described in the Wechsler Memory Scale Manual (n=316). These scores were 
corrected for age 3. Patients’ scores on the Rey Complex Figure were compared to reference data 




Norm data for the divided attention, visual scanning and alertness subtests were provided by the 
test authors within the Test of Attentional Performance Version 2.2. 5. A correction for age and sex 
was applied.
Executive functioning
The results of the semantic subtest of the Verbal Fluency Test were compared to a reference group 
(n=464) consisting of healthy participants aged 17-90 11. The scores were corrected for age and 
education. The scores of the phonemic subtest of the Verbal Fluency Test were compared to a 
reference group (n=570) consisting of participants aged 17-90 11 and corrected for education. The 
results of the TMT were compared to a reference group (n=478), consisting of healthy participants 
aged 17-90 11. The scores were corrected for age, sex and education.
 
Social cognition
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General discussion and summary
General discussion and conclusions
In the present thesis, we focused on the effects of different treatment options on cognition in 
patients with pituitary diseases. Reliable information on the possible side effects of different treat- 
ment options is of particular importance for clinicians and patients to allow an informed dis-
cussion and decision on treatment strategies. Furthermore, knowledge of the impact of specific 
treatments on cognition might also serve as a basis for theory driven approach to the evaluation 
of treatment strategies.
 
The effects of radiotherapy on cognition in patients with a nonfunctioning pituitary adenoma
The aim of chapter 2 was to assess memory and executive functioning in a large (n = 84) ho-
mogeneous group of NFA patients. We specifically focused on NFA patients, since inconsistent 
results of previous studies were most likely the consequence of heterogeneous and small patient 
groups. In subjects with hormone-producing tumors, like Cushing’s disease, the hormone over-
production itself may also have an effect on cognition. The second aim of this chapter was to 
compare patients who received both surgery and radiotherapy with those who only underwent 
surgery. It was found that NFA patients displayed a worse cognitive performance compared to 
reference populations on both verbal memory and executive functioning. However, the effects of 
radiotherapy were at most very small and unlikely to be of clinical relevance.
 Since relatively small effects of radiotherapy on cognition in NFA patients could not be exclud- 
ed (e.g. due to different radiotherapy techniques and therefore dose distribution), we refined the 
strategy and related radiation exposure of brain areas of interest (i.e. the hippocampus and the 
prefrontal cortex) to cognitive performance typically associated with these brain areas (chapter 
3). This follow-up study showed that current multiple field radiotherapy techniques do not have 
a significant negative effect on memory and executive functioning in patients with NFA. Also, 
a dose-response relationship could not be established. Although this was found in a group of 
patients with similar dose prescriptions, it can be argued that the different multiple field radiother-
apy techniques applied seem to operate within safe radiotherapy dose boundaries.
 White matter lesions and cerebral atrophy are well known radiologically detectable brain ab-
normalities following radiotherapy, which are reported to be associated with diminished cogni-
tive performance 1,2. So far, imaging studies on the association between brain abnormalities after 
radiotherapy and cognition have focused on patients without fixed tumor localization. These 
studies particularly included patients with low grade gliomas 1-3 in whom different cognitive do-
mains are affected because of varying tumor localization, which leads to heterogeneous results. 
Therefore, we assessed and compared brain abnormalities on imaging in relation to cognitive 
impairments in NFA patients who have a fixed tumor location (chapter 4). The results of this study 
showed that the frequency of brain abnormalities did not differ between NFA patients with and 
without cognitive impairments in the domains of verbal memory and executive functioning.
 In conclusion, the results of chapters 2, 3 and 4 indicate that current multiple field radiother- 
apy techniques and fractionated radiation dose regimens – applied in addition to surgery - do not 




A possible explanation for our findings might be that there is some kind of dose related threshold 
for radiotherapy to injure the brain and cause cognitive impairment, suggesting that only above 
this threshold a dose-response relationship can be found. The results of chapters 2, 3 and 4 indi-
cate that all radiotherapy techniques which have been used over the years for the treatment of 
NFA patients in our center appear to operate within safe radiotherapy dose boundaries and do 
not have a major effect on memory and executive functioning.
 Another explanation could also be that the adverse effects of radiotherapy have not become 
evident yet, since deterioration in cognitive functions might appear only after a few years 3. How- 
ever, at slightly higher radiation doses than applied in our studies in chapters 2, 3 and 4, some 
have reported a decrease in executive functioning already after six months post radiotherapy in 
patients with primary brain tumors 4. Nevertheless, time since radiotherapy was not associated 
with cognitive functioning in the studies presented in chapters 2, 3 and 4. These studies included 
patients with long follow-up time since radiotherapy and therefore limited additional damage is 
expected. Whether the potential radiotherapy induced damage can change over time can only 
be answered with long-term follow-up studies.
 However, even though no differences were found between irradiated and unirradiated pa-
tients, NFA patients displayed a worse cognitive performance compared to reference samples. 
These cognitive impairments can be the consequence of surgery, however, previous studies 
indicated that it is more likely that patients already exhibit such impairments before surgery. For 
example, it was demonstrated in patients with frontal meningiomas that surgery did not impair 
patients’ cognitive functioning, since pre- and postoperative assessments revealed no significant 
differences with regard to cognition 5. This idea is consistent with a study of Tucha and colleagues 
who found that more than 90% of patients with brain tumors have cognitive impairments at 
baseline 6. Another explanation for impaired cognitive performance of NFA patients might be that 
nonspecific psychological factors associated with having a chronic illness have a negative effect 
on cognition 7. Alternatively, hormonal insufficiency secondary to the tumor and/or its treatment 
could also be responsible for impaired cognitive functioning of patients with NFA. In particular, 
growth hormone (GH) and glucocorticoids may play an important role in cognition, as will also 
be discussed in the following sections.
 
A strength of the aforementioned studies is the fixed position of the pituitary tumor in NFA 
patients excluding potential confounding influences of the localization of both brain tumor 
and subsequent targeted focal radiotherapy. Also, as already mentioned, compared to previous 
studies a relatively large group of patients with a single diagnosis was included in chapter 2.
 There are, however, some limitations that should be taken into account. First, the disease char- 
acteristics (e.g. larger and more invasive tumors) of patients who receive both surgery and radio-
therapy are somewhat different than the disease characteristics of NFA patients who only receive 
surgery, indicating a possible selection bias. Second, cognition was only assessed with a relatively 
limited test battery and the studies described in chapters 2, 3 and 4 only focused on memory 
and executive functioning. A more sensitive approach would be to use several tests to assess the 
cognitive domains of memory and executive functioning. In addition, other cognitive domains 
should be examined as well.
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The effects of previous growth hormone excess and current medical treatment for acromegaly on 
cognition
Changes in cognitive functioning can be expected as a consequence of GH excess or GH deficien-
cy 8-12. The aim of chapter 5 was two-fold. First, to compare cognitive performance of acromeg- 
aly patients with a persistent disease (i.e. on GH suppressive medication) with the performance of 
acromegaly patients who were in remission. Until now, no research is available on the effects of 
medical treatment for acromegaly on cognition. Learning more about the association between 
medical treatment for acromegaly and cognitive performances is important, since studies indicat- 
ed that GH suppressive medication can lead to changes in diurnal GH profile, despite Insulin-like 
growth factor-1 (IGF-1) values being within the normal range 13, 14. The second aim was to com-
pare cognitive performance of acromegaly patients with NFA patients, to investigate the effects 
of previous GH excess on cognition. So far, most studies on the effects of GH excess on cognition 
compared untreated acromegaly patients 11 or acromegaly patients who are not fully biochemi-
cally controlled 12 with healthy participants. These kinds of comparisons appear to be less infor-
mative since psychological factors associated with having a chronic illness might influence the 
results 7. Therefore, we compared acromegaly patients with NFA patients, since NFA patients share 
many disease characteristics with acromegaly patients but do not have GH excess.
 Our study showed that acromegaly and NFA patients displayed a decreased cognitive per-
formance compared to reference populations, however, previous GH excess had no effect on 
cognition. In addition, Z-scores did not differ in cognition from both acromegaly patients on GH 
suppressive medication with normal IGF-1 Z-scores compared to both acromegaly patients who 
were in remission and NFA patients. Although not measured directly, diurnal GH profiles are likely 
to be different between patient groups in this study. Our findings suggest that disease control 
by IGF-1 alone might be sufficient to prevent cognitive decline. This conclusion needs, however, 
to be confirmed in future studies, since our study had a cross-sectional design and was therefore 
limited to infer causality. Additional studies should also determine GH profiles to see what the 
actual effects are of possible abnormal GH profiles on cognition.
 A limitation of this study was that there were several significant differences between acro-
megaly and NFA patients regarding their baseline characteristics, which potentially could have 
influenced cognition. These groups particularly differed with regard to the frequency of radiother- 
apy, i.e. acromegaly patients with persistent disease received radiotherapy more often than both 
acromegaly patients who were in remission and NFA patients. Based on the results of the previ-
ous chapters and a regression analysis focusing on the effects of radiotherapy on cognition in 
acromegaly patients, we concluded that the differences in frequency of radiotherapy did not in-
fluence the results reported in chapter 5. Furthermore, NFA patients displayed significantly lower 
IGF-1 Z-scores compared to the acromegaly patients. Even though NFA patients were probably 
not GH deficient, it is possible that IGF-1 Z-scores closer to zero are more favorable for cognition 
compared to IGF-1 Z-scores that are more than one standard deviation below zero.
 We concluded that patients with acromegaly show impairments in memory and executive 
functioning. However, based on this study, endocrinologists can inform acromegaly patients with 
an active disease that GH suppressive medication has no additional detectable negative effect on 
memory and executive functioning. Also, cognition is not negatively influenced by previous GH 
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excess. This conclusion needs, however, to be confirmed in prospective studies, since our study 
had a cross-sectional design and was therefore limited to infer causality.
 
The effects of hydrocortisone substitution on cognition in patients with secondary adrenal insuf-
ficiency due to various pituitary diseases
Patients with secondary adrenal insufficiency (SAI), as a consequence of pituitary disease, are 
treated with glucocorticoids dose regimens that inevitably result in over- or under-replacement 
during certain periods of the day which can affect cognitive functioning. Deficits in memory, 
executive functioning, attention and social cognition were expected since these functions rely 
on brain structures containing high concentrations of glucocorticoids receptors 15, 16. In chapter 
6 we described the results of the first study on the effects of long-term physiological doses of 
hydrocortisone and cognitive functioning in patients treated for SAI. It is important to determine 
these long-term effects, since cognitive impairments usually affect everyday functioning. Our stu-
dy described in chapter 6 showed that patients with pituitary diseases all of whom were treated 
for SAI are selectively impaired in memory, attention, executive functions and social cognition 
compared to reference samples. These selective impairments might at least in part be deter-
mined by the material that has to be processed (verbal versus non-verbal, coherent versus inco-
herent). Furthermore, various forms of treatment appeared to be associated with cognition in SAI 
patients. Both, characteristics of radiotherapy and surgery were associated with a poorer mem- 
ory, executive functioning, attention and social cognition. In chapter 2 and chapter 3, we did 
not reveal such effects of radiotherapy and surgery when comparing NFA patients to reference 
samples. Also regarding self-reported cognition these effects were not found 17. An explanation 
for this apparent discrepancy might be that a more comprehensive test battery was used in the 
study described in chapter 6, which might be more sensitive in detecting cognitive impairments 
in pituitary patients.
When a more clinical individual approach was used, it was found that many SAI patients showed 
impairments in the cognitive domains of memory (80%), attention (85%), executive functioning 
(43%) and social cognition (37%). These results indicate that SAI patients might benefit from cog-
nitive rehabilitation programs, which are already applied on patients with primary brain tumors 
18. Compensatory techniques can among other benefits be helpful in teaching patients how to 
manage their daily life, since problems in attention and executive function are also reported in 
outpatient clinics. Furthermore, treatment can also be directed on improving social cognitive 
skills to maintain good interpersonal relations. With regard to memory, the results specifically 
indicated that the consolidation of verbal information appears to be intact in SAI patients, how-
ever, these patients do show difficulties with encoding and retrieving information from memory. 
Furthermore, patients treated for SAI appear to pay more attention to visual stimuli as compared 
to auditory stimuli. Taking these factors into account, rehabilitation programs in these patients 




Conclusions and future directions
The present thesis describes the effects of 1) radiotherapy, 2) GH excess in history and current GH 
suppressive medication and 3) hydrocortisone substitution therapy on cognition in patients with 
pituitary diseases. Based on the results of this thesis it can be concluded that:
Current multiple field radiotherapy techniques and fractionated radiation dose regimens do 
not appear to have a major effect on memory and executive functioning in patients with 
NFA.
Previous GH excess in patients is not negatively associated with cognition.
Current medical treatment for GH excess is not related to cognition.
Patients with various pituitary diseases who all were treated for SAI have selective impairments 
in the cognitive domains of memory, attention, executive functions and social cognition.
 
To further elucidate the effects of treatment on cognition in patients with pituitary diseases sev- 
eral recommendations can be made. First, regarding the effects of surgery and radiotherapy on 
cognition it is recommended to perform longitudinal studies with comprehensive test batteries 
and a baseline measurement before any kind of treatment is started. A study like this will be the 
only way to distinguish between the effects of disease and treatment related factors on cogni-
tion. A longitudinal study including a baseline assessment is also important, since there is a lot of 
inter-individual variability in the ability to recover after brain pathology. This inter-individual vari-
ability has been explained by the construct of “cognitive reserve”. Cognitive reserve refers to a set 
of variables, including education, intelligence, and mental stimulation, which putatively allow the 
brain to adapt to -and hence mask- underlying pathologies by maintaining cognitive functioning 
despite underlying neural changes 19. A consequence might be that patients with pituitary dis- 
eases and a high cognitive reserve show less cognitive impairments than patients with pituitary 
diseases with a low cognitive reserve. Cognitive reserve thus appears to be a factor that should 
be taken into account in future studies.
 Second, when comparing patient data with reference samples, as done in studies in this the-
sis, it is important to keep in mind that there are differences regarding the way reference data 
have been collected and the way the data in the studies of this thesis have been collected. For 
example, there might be an effect of the order in which the tests were applied. Also, more gener- 
al psychological factors such as fatigue or motivation might be of influence, particularly if long 
and extensive test batteries are used (e.g. Chapter 6). Future studies on cognition in patients with 
pituitary diseases should therefore include a control group, which consists of healthy individuals 
who are matched for age, sex and education to the group of patients.
 Finally, it needs to be taken into account that a cross sectional study was used to determine 
the effects of hydrocortisone on cognition. Cross sectional studies are effective when evaluating 
large groups of patients and determining the associations with treatment characteristics. How-
ever, no conclusions can be drawn about the causal relationship between hydrocortisone expo-
sure and cognitive outcome, since exposure and outcome are determined at the same time. For 
future research it is therefore recommended to assess and compare in a randomized double blind 
design the effects of a low physiological hydrocortisone substitution dose with the effects of a 
high physiological hydrocortisone substitution dose on cognition in order to learn more about 
General discussion and summary
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the effects of hydrocortisone (or cortisone acetate) on cognition in patients treated for SAI. This 
kind of study is also informative regarding the effects of other pituitary hormones on cognition.
 In summary, the following findings in our studies are relevant for clinicians who care for 
pituitary patients:
1. Invariably we found cognitive defects in pituitary patients. Doctors should be aware that this is 
found frequently in patients visiting the outpatient clinics and may have clear repercussions. Al-
though not the topic of this study consequences of this may be the inability to properly carry out 
your work, difficulties in managing the day and reduced self confidence. There appears to be a 
compensatory mechanism (i.e. enhanced visual memory) that enables the patients to adapt to a 
certain extent. This is a finding that may provide reassurance in patients and potentially provides 
the opportunity to develop a cognitive rehabilitation program.
2. Clinicians should be aware of safety profiles of treatment modalities. Radiotherapy for pituitary 
diseases is not negatively associated with major effects on cognition, and this argument should 
not be used to postpone or withhold radiotherapy to patients who can benefit from it. Further, in 
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In dit proefschrift staan de resultaten van studies naar de effecten van verschillende behandel-
mogelijkheden op het cognitieve functioneren van patiënten met hypofyse aandoeningen be-
schreven. Betrouwbare informatie over de mogelijke effecten van verschillende behandelingen 
is belangrijk voor clinici en patiënten zodat zij een geïnformeerde discussie kunnen voeren en 
beslissing kunnen nemen. De kennis over de impact van specifieke behandelingen op het cogni-
tieve functioneren zou  tevens kunnen dienen als een basis voor een meer theoretische evaluatie 
van verschillende behandelopties.
De effecten van radiotherapie op cognitie bij patiënten die zijn behandeld voor een 
niet functionerend hypofyse adenoom
Het doel van hoofdstuk 2 was om het geheugen en het executief functioneren te beoordelen in 
een grote groep patiënten (n = 84) die behandeld zijn voor een niet functionerend hypofyse ade-
noom (NFA). We hebben ons gefocust op deze aandoening omdat de wisselende uitkomsten van 
verschillende studies zeer waarschijnlijk zijn veroorzaakt door de inclusie van kleine en hetero-
gene patiënten populaties. Bovendien hebben patiënten met een NFA het voordeel dat zij geen 
voorgeschiedenis kennen met daarin een overmatige productie van één bepaald hormoon. Dit 
laatste is bijvoorbeeld wel het geval bij patiënten met de ziekte van Cushing, waarbij een teveel 
aan cortisol (stresshormoon) het cognitief functioneren kan beïnvloeden. Het tweede doel in 
dit hoofdstuk was om patiënten die alleen een chirurgische behandeling hebben ontvangen te 
vergelijken met patiënten die aanvullend aan de chirurgie ook radiotherapie hebben gekregen. 
De resultaten van het onderzoek lieten zien dat de groep NFA patiënten in zijn geheel slechter 
scoorde op zowel de verbale geheugentest als ook op de executieve functie test wanneer hun 
testprestaties werden vergeleken met testprestaties van mensen uit referentie populaties. De ef-
fecten van radiotherapie op het cognitieve functioneren lijken hierbij zeer klein te zijn en zijn 
waarschijnlijk klinisch niet relevant.
 Echter, omdat kleine effecten van radiotherapie op cognitie bij NFA patiënten niet kunnen 
worden uitgesloten (bijv. vanwege het gebruik van verschillende radiotherapeutische technieken 
en daardoor verschillende dosesverdelingen in het brein), werd besloten om de onderzoeksme-
thode te verfijnen. In hoofdstuk 3 hebben we gekeken of er een relatie bestaat tussen de hoe-
veelheid bestraling op een specifiek hersengebied en de cognitieve functie die een beroep doet 
op dat specifieke hersengebied. Als hersengebieden werden de hippocampus en de prefrontale 
cortex gekozen, gebieden die belangrijk zijn voor respectievelijk het geheugen en de executieve 
functies. Dit vervolgonderzoek liet zien dat de huidige radiotherapeutische technieken geen ne-
gatieve invloed lijken te hebben op het geheugen en het executief functioneren bij patiënten 
die zijn behandeld voor een NFA. Tevens vonden wij geen relatie tussen de hoeveelheid bestra-
ling op de hippocampus en het geheugen en ook niet tussen de hoeveelheid bestraling op de 
prefrontale cortex en het executief functioneren. De radiotherapeutische technieken zoals deze 
staan beschreven in hoofdstuk 2 en 3 lijken derhalve veilig te zijn.
 Radiotherapie wordt ook in verband gebracht met hersenafwijkingen zoals witte stof schade 
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en cerebrale atrofie welke geassocieerd worden met een verminderd cognitief functioneren. Tot 
dusver hebben de beeldvormende studies naar de associaties tussen deze structurele hersenaf-
wijkingen en het cognitief functioneren gebruik gemaakt van patiënten met verschillende tumor 
lokalisaties. Dit waren meestal patiënten met laaggradige gliomen waarbij verschillende cogni-
tieve domeinen zijn aangedaan vanwege verschillende lokalisaties van de tumor in het brein wat 
leidt tot wisselende resultaten. In het in hoofdstuk 4 beschreven onderzoek werd er daarom voor 
gekozen om structurele hersenafwijkingen te beoordelen in relatie tot het cognitieve functione-
ren bij patiënten die zijn behandeld voor een NFA aangezien bij deze patiënten dus sprake is van 
een gefixeerde tumor lokalisatie. De resultaten van deze studie lieten zien dat de frequentie van 
structurele hersenafwijkingen niet verschilt tussen patiënten met beperkingen in de cognitieve 
domeinen geheugen en executief functioneren en patiënten zonder beperkingen in het geheu-
gen en het executief functioneren.
 Kortom, de resultaten van de hoofdstukken 2, 3 en 4 suggereren dat de huidige radiotherapie 
technieken en de gefractioneerde bestralingsplannen die NFA patiënten krijgen in aanvulling op 
hun chirurgische behandeling geen groot negatief effect lijken te hebben op het geheugen en 
het executief functioneren.
 
Eén van de mogelijke verklaringen voor onze bevindingen is dat er sprake is van een soort dosis 
gerelateerde drempelwaarde voor radiotherapie voordat deze leidt tot cognitieve beperkingen, 
wat suggereert dat alleen boven die drempelwaarde een dosis-respons relatie kan worden ge-
vonden. De resultaten van de hoofdstukken 2, 3 en 4 suggereren dat alle radiotherapeutische 
technieken en gefractioneerde bestralingsplannen die in de afgelopen decennia zijn gebruikt 
voor de behandeling van NFA patiënten in ons centrum onder deze drempelwaarde lijken te 
opereren en daardoor geen grote negatieve gevolgen lijken te hebben voor het geheugen en 
het executief functioneren.
 Een andere mogelijkheid is dat de nadelige effecten van radiotherapie nog niet tot uiting 
zijn gekomen en dat cognitieve beperkingen pas tot uiting komen na een aantal jaren. Hier pleit 
echter tegen dat andere onderzoekers bij enigszins hogere radiotherapeutische doseringen dan 
die in onze studies werden onderzocht, al  zes maanden na de radiotherapie cognitief verval 
rapporteerden bij patiënten met primaire hersentumoren. In de studies die staan beschreven 
in de hoofdstukken 2, 3 en 4 was de tijd sinds radiotherapie niet geassocieerd met het cognitief 
functioneren. Aangezien in onze studies patiënten zijn geïncludeerd met een lange follow-up tijd 
sinds radiotherapie, verwachten wij geringe aanvullende schade. Of deze potentiële radiothe-
rapeutisch geïnduceerde schade kan veranderen over tijd kan alleen worden beantwoord met 
behulp van lange termijn follow-up studies.
Hoewel er geen verschillen werden gevonden tussen de bestraalde en niet-bestraalde patiën-
ten, lieten de NFA patiënten wel verminderde cognitieve prestaties zien in vergelijking met de 
testprestaties van mensen uit referentie populaties. Deze cognitieve beperkingen kunnen het 
gevolg zijn van de chirurgische ingreep, maar eerdere studies suggereren dat het waarschijnlijker 
is dat patiënten reeds cognitieve beperkingen vertoonden voorafgaand aan de operatie. Zo werd 
bijvoorbeeld bij mensen met frontale meningeomen aangetoond dat een operatie waarschijnlijk 
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niet van invloed was op het cognitief functioneren, omdat pre- en postoperatieve cognitieve 
prestaties niet significant van elkaar verschilden. Deze suggestie is in overeenstemming met een 
studie van Tucha en collega’s die vonden dat meer dan 90% van de patiënten met hersentumo-
ren cognitieve beperkingen laat zien tijdens een baseline bepaling. Een andere verklaring voor de 
verminderde cognitieve prestaties van NFA patiënten zou kunnen zijn dat aspecifieke psycholo-
gische factoren, die geassocieerd zijn met het hebben van een chronische ziekte, een negatief ef-
fect hebben op het cognitieve functioneren. Ten slot kan het ook zo zijn dat de hormonale insuf-
ficiëntie secundair aan de tumor en/of de behandeling verantwoordelijk is voor een verminderd 
cognitief functioneren van patiënten met een NFA. In het bijzonder kunnen het groeihormoon 
(GH) en glucocorticoïden van invloed zijn op het cognitief functioneren, zoals wordt besproken 
in de volgende paragrafen.
 Eén van de sterke punten van de bovengenoemde studies is de eenduidige lokalisatie van 
de hypofyse tumor bij NFA patiënten met als gevolg dat mogelijke verstorende invloeden van de 
lokalisatie van zowel hersentumor als ook de daaropvolgende gerichte focale radiotherapie kun-
nen worden uitgesloten. Bovendien, zoals al eerder werd vermeld, is een relatief grote homogene 
groep patiënten geïncludeerd in hoofdstuk 2.
 Er zijn echter ook zwakke punten waarmee rekening moet worden gehouden. Ten eerste, de 
ziekte kenmerken (bv. grotere en meer invasieve tumoren) van patiënten die zowel chirurgie als 
radiotherapie ontvangen, zijn anders dan de ziekte kenmerken van NFA patiënten die alleen chi-
rurgie ontvangen, wat wijst op een mogelijke selectiebias. Ten tweede, het cognitieve functione-
ren werd alleen met een relatief beperkte testbatterij onderzocht en de studies zoals beschreven 
in de hoofdstukken 2, 3 en 4 beoordeelden alleen het geheugen en het executief functioneren. 
Een gevoeligere methode zou zijn om verschillende tests te gebruiken om de cognitieve domei-
nen geheugen en executieve functioneren te beoordelen. Daarnaast is het van belang dat er ook 
onderzoek wordt gedaan naar andere cognitieve domeinen.
De effecten van een teveel aan groeihormoon in de voorgeschiedenis en de huidige 
medische behandeling voor acromegalie op cognitie
Veranderingen in het cognitief functioneren kunnen het gevolg zijn van een overmaat aan GH 
of juist een GH deficiëntie. Het doel van hoofdstuk 5 was tweeledig. Ten eerste werden de cog-
nitieve prestaties van acromegalie patiënten met een aanhoudende ziekte (d.w.z. op GH onder-
drukkende medicatie) vergeleken met de cognitieve prestaties van acromegalie patiënten die in 
remissie waren. Tot op heden is er geen onderzoek gedaan naar de effecten van de medische be-
handeling van acromegalie op het cognitieve functioneren. Het is echter belangrijk om meer te 
leren over de associatie tussen de medische behandeling voor acromegalie en cognitieve presta-
ties, omdat eerdere studies aantonen dat GH onderdrukkende medicatie kan leiden tot verande-
ringen in het dagelijkse GH profiel, ondanks dat de waarde van het Insuline gelijkende groeifactor 
(IGF-1) binnen de normale range ligt. Het tweede doel van hoofdstuk 5 was om de cognitieve 
prestaties van acromegalie patiënten te vergelijken met de cognitieve prestaties van NFA patiën-
ten zodat de gevolgen van een overmaat aan GH in de voorgeschiedenis konden worden onder-
zocht. Tot dusver vergeleken de meeste studies naar de effecten van een overmaat aan GH op het 
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cognitief functioneren onbehandelde acromegalie patiënten of acromegalie patiënten die niet 
volledig biochemisch gecontroleerd waren met gezonde vrijwilligers. Dergelijke vergelijkingen 
lijken minder informatief te zijn, omdat psychologische factoren die geassocieerd zijn met het 
hebben van een chronische ziekte de resultaten kunnen beïnvloeden. Om deze reden hebben 
wij acromegalie patiënten met NFA patiënten vergeleken, omdat NFA patiënten veel kenmerken 
met acromegalie patiënten delen, maar geen overmaat aan GH in de voorgeschiedenis kennen.
 De resultaten van hoofdstuk 5 toonden aan dat acromegalie en NFA patiënten beide vermin-
derde cognitieve prestaties lieten zien in vergelijking met referentiepopulaties en dat een voor-
geschiedenis van een overmaat aan GH geen blijvend effect lijkt te hebben op het cognitieve 
functioneren. Bovendien verschilden de prestaties op de cognitieve tests van acromegalie pa-
tiënten op GH onderdrukkende medicatie (met IGF-1 scores die in de normale range liggen) niet 
van de prestaties van zowel acromegalie patiënten die in remissie waren als van NFA patiënten. 
Hoewel niet direct gemeten, verschilden de dagelijkse GH profielen waarschijnlijk tussen de groe-
pen patiënten die onderzocht zijn in onze studie in hoofdstuk 5. Onze bevindingen suggereren 
dat de controle van de ziekte  door alleen IGF-1 voldoende zou kunnen zijn om cognitieve be-
perkingen te voorkomen. Deze conclusie moet echter worden bevestigd in toekomstige studies 
vanwege het cross-sectionele design van onze studie waardoor we geen uitspraak kunnen doen 
over de causaliteit. Aanvullende onderzoeken zouden ook GH profielen moeten bepalen om te 
zien wat de werkelijke gevolgen zijn van eventuele afwijkende GH profielen op het cognitieve 
functioneren.
 Een beperking van dit onderzoek was dat er een aantal belangrijke baseline verschillen waren 
tussen de acromegalie patiënten en de NFA patiënten, die mogelijk een invloed hebben gehad 
op het cognitieve functioneren. Deze groepen verschilden vooral wat betreft het krijgen van ra-
diotherapie; de acromegalie patiënten met een persisterende ziekte kregen vaker radiotherapie 
dan de acromegalie patiënten die in remissie waren en de NFA patiënten. Op basis van de resulta-
ten van de voorgaande hoofdstukken en een regressieanalyse naar de effecten van radiotherapie 
op cognitie bij acromegalie patiënten, kan worden aangenomen dat het verschil in frequentie 
van radiotherapie de resultaten zoals beschreven in hoofdstuk 5 niet heeft beïnvloed. Bovendien 
hadden de NFA patiënten significant lagere IGF-1 Z-scores in vergelijking met de acromegalie 
patiënten. Hoewel de NFA patiënten waarschijnlijk niet GH deficiënt waren, suggereert onder-
zoek van anderen dat IGF-1 scores die dichter bij het gemiddelde van de normale range liggen 
gunstiger zijn voor het cognitieve functioneren dan IGF-1 scores die juist meer afwijken van het 
gemiddelde in de normale range.
 We kunnen dus concluderen dat patiënten met acromegalie een verminderde prestatie laten 
zien op het gebied van het geheugen en het executieve functioneren. Echter, op basis van deze 
studie, kunnen endocrinologen acromegalie patiënten met een actieve ziekte informeren over 
het feit dat GH onderdrukkende medicatie geen additionele aantoonbare beperkingen in het ge-
heugen en het executief functioneren tot gevolg heeft. Ook lijkt het  cognitieve functioneren niet 
negatief te worden beïnvloed door een overmaat aan GH in de voorgeschiedenis. Deze conclusie 
moet echter worden bevestigd in prospectieve studies.
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De effecten van hydrocortison substitutie op cognitie bij patiënten met secundaire bij-
nierschorsinsufficiëntie door verschillende hypofyse aandoeningen
Patiënten met secundaire bijnierschorsinsufficiëntie, als gevolg van een hypofyse-aandoening, 
worden behandeld met verschillende doseringen glucocorticoïden die onvermijdelijk leiden tot 
over- of ondersubstitutie gedurende bepaalde perioden van de dag. Deze over- of ondersub-
stitutie kan van invloed zijn op het cognitief functioneren. Veranderingen in het geheugen, de 
executieve functies, de aandacht en de  sociale cognitie kunnen worden verwacht, aangezien 
deze cognitieve functies een beroep doen op hersenstructuren die hoge concentraties glucocor-
ticoïden-receptoren bevatten. In hoofdstuk 6 worden  de resultaten beschreven van de eerste 
studie naar het cognitief functioneren van patiënten die langdurig zijn behandeld voor secun-
daire bijnierschorsinsufficiëntie met fysiologische doseringen hydrocortison. De resultaten van 
de studie laten zien dat  patiënten met hypofyse aandoeningen – die allen werden behandeld 
voor secundaire bijnierschorsinsufficiëntie - selectieve beperkingen laten zien in het geheugen, 
de aandacht, de executieve functies en de sociale cognitie in vergelijking met referentie popu-
laties van gezonde personen. Deze selectieve stoornissen lijken gedeeltelijk te worden bepaald 
door het materiaal dat moet worden verwerkt (verbaal versus non-verbaal, coherent versus in-
coherent). Bovendien lijken verschillende behandelmogelijkheden geassocieerd te zijn met het 
cognitieve functioneren van patiënten met secundaire bijnierschorsinsufficiëntie. Zowel kenmer-
ken van radiotherapie als ook van chirurgie zijn geassocieerd met een verminderd geheugen, 
executief functioneren, aandacht en sociale cognitie. In hoofdstuk 2 en hoofdstuk 3 hebben we 
dergelijke effecten van radiotherapie en chirurgie niet gevonden bij het vergelijken van NFA pa-
tiënten met de testprestaties van mensen uit referentie populaties. Ook ten aanzien van zelfge-
rapporteerde cognitieve beperkingen werden deze effecten niet gevonden. Een verklaring voor 
deze schijnbare discrepantie zou kunnen zijn dat een meer uitgebreide testbatterij werd gebruikt 
in de studie zoals beschreven in hoofdstuk 6, die mogelijk gevoeliger is in het opsporen van 
cognitieve beperkingen bij patiënten met hypofyse aandoeningen.
Wanneer meer op individueel niveau werd gekeken, dan zien we dat veel patiënten met se-
cundaire bijnierschorsinsufficiëntie beperkingen vertonen in het geheugen (80%), de aandacht 
(85%), het executief functioneren (43%) en de sociale cognitie (37%). Deze resultaten laten zien 
dat deze patiënten mogelijk kunnen profiteren van cognitieve revalidatieprogramma’s. Dergelijke 
programma’s worden al toegepast bij patiënten met primaire hersentumoren. Het aanleren van 
compensatie technieken kan onder andere nuttig zijn om patiënten te helpen om hun dagelijks 
leven goed te beheren, vooral omdat problemen in de aandacht en de  executieve functies (bijv. 
planning) gemeld worden tijdens poliklinische bezoeken. Bovendien kan de behandeling ook 
worden gericht op het verbeteren van sociaal cognitieve vaardigheden zodat goede interper-
soonlijke relaties kunnen worden onderhouden. De resultaten van de geheugentests laten zien 
dat de consolidatie van verbale informatie intact lijkt te zijn bij patiënten met  secundaire bijnier-
schorsinsufficiëntie,  maar dat deze patiënten problemen hebben met het inprenten en ophalen 
van informatie uit het geheugen. Bovendien lijken de patiënten meer aandacht te besteden aan 
visuele stimuli in vergelijking met auditieve stimuli. Revalidatie programma’s zouden hier reke-
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ning mee kunnen houden door meer gebruik te maken van visuele aanwijzingen die het ophalen 
van informatie uit het geheugen kunnen vergemakkelijken.
Conclusies en aanbevelingen voor de toekomst
In dit proefschrift worden de resultaten beschreven van 1) radiotherapie, 2) een overmaat aan 
GH in de voorgeschiedenis en van GH onderdrukkende medicatie en 3) hydrocortison substitutie 
therapie (als onderdeel van vaak meervoudige hormonale substitutietherapie) in relatie tot cog-
nitie bij patiënten die behandeld zijn voor hypofyse aandoeningen. Op basis van dit proefschrift 
kunnen we het volgende concluderen:
De huidige radiotherapie technieken en gefractioneerde bestralingsplannen lijken geen 
grote invloed te hebben op het geheugen en het executief functioneren bij patiënten met 
een NFA.
Een voorgeschiedenis van een overmaat aan GH lijkt niet schadelijk te zijn voor het cognitieve 
functioneren.
De huidige medische behandeling voor een overmaat aan GH lijkt niet gerelateerd te zijn aan 
het cognitieve functioneren.
Patiënten met verschillende hypofyse aandoeningen, die allen werden behandeld voor 
secundaire bijnierschorsinsufficiëntie, hebben selectieve stoornissen in de cognitieve 
domeinen van het geheugen, de aandacht, de executieve functies en de sociale cognitie.
Meerdere aanbevelingen kunnen worden gedaan om de effecten van behandeling op het cogni-
tieve functioneren bij patiënten met hypofyse aandoeningen verder te ontrafelen. Ten eerste ad-
viseren we om - met betrekking tot de effecten van chirurgie en radiotherapie op het cognitieve 
functioneren - longitudinale studies uit te voeren met uitgebreide test batterijen en een baseline 
meting voordat gestart wordt met behandelen. Met een dergelijk onderzoek kan onderscheid 
gemaakt worden tussen de effecten van de ziekte enerzijds en de effecten van behandeling op 
cognitie anderzijds. Een longitudinaal onderzoek inclusief een baseline bepaling is tevens be-
langrijk, omdat er veel interindividuele variabiliteit is in het vermogen om te herstellen nadat er 
schade is ontstaan aan het brein. Deze interindividuele variabiliteit is mogelijk te verklaren door 
het construct “cognitieve reserve”. Dit verwijst naar een set van variabelen, waaronder onderwijs, 
intelligentie en mentale stimulatie, die vermoedelijk mensen in staat stellen om zich aan te pas-
sen aan de nieuwe situatie - en daarmee te kunnen compenseren voor een onderliggende pa-
thologie. Het cognitief functioneren kan dan behouden worden, ondanks achterliggende neurale 
veranderingen. Een gevolg hiervan zou kunnen zijn dat patiënten met hypofyse aandoeningen 
en een hoge cognitieve reserve minder cognitieve stoornissen tonen dan patiënten met hypo-
fyse aandoeningen en een lage cognitieve reserve. Het construct van cognitieve reserve lijkt dus 
een factor waarmee rekening moet worden gehouden in toekomstige studies.
 Ten tweede, bij het vergelijken van patiëntgegevens met testprestaties van referentie popu-
laties, zoals gedaan in studies in dit proefschrift, is het belangrijk om in gedachten te houden dat 
er verschillen zijn ten aanzien van de manier waarop referentiegegevens zijn verzameld en de 
manier waarop de gegevens in de studies van dit proefschrift zijn verzameld. Zo kan er een effect 
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zijn van de volgorde waarin de tests zijn afgenomen. Ook kunnen meer algemene psychologi-
sche factoren zoals vermoeidheid of motivatie van invloed zijn, vooral als lange en uitgebreide 
testbatterijen worden gebruikt (bijv. hoofdstuk 6). Toekomstige studies gericht op het cognitieve 
functioneren van patiënten met hypofyse aandoeningen zouden daarom ook een controlegroep 
moeten includeren, die bestaat uit gezonde individuen die zijn gematcht voor leeftijd, geslacht 
en opleiding aan de patiëntengroep.
 Ten slotte moet er rekening worden gehouden met het feit dat er een cross-sectioneel 
onderzoek werd gedaan naar de effecten van hydrocortison op cognitie. Cross-sectionele studies 
zijn effectief bij het evalueren van grote groepen patiënten en het bepalen van de associaties met 
behandelkarakteristieken. Er kunnen echter geen conclusies worden getrokken over het causale 
verband tussen hydrocortison gebruik en cognitief functioneren, omdat deze op hetzelfde mo-
ment zijn bepaald. Voor toekomstig onderzoek wordt daarom geadviseerd om een gerandomi-
seerd dubbelblind onderzoek te doen naar de effecten van een lage en een hoge fysiologische 
hydrocortison dosering op het cognitief functioneren. Op deze manier kunnen we meer leren 
over de effecten van verschillende doseringen hydrocortison (of cortisonacetaat) op het cogni-
tieve functioneren van patiënten die zijn behandeld voor secundaire bijnierschorsinsufficiëntie. 
Dergelijk onderzoek zou ook informatief kunnen zijn om inzicht te krijgen in de relatie tussen 
andere hypofyse hormonen en cognitie.
 Samenvattend kunnen de volgende bevindingen in onze studies relevant zijn voor clinici die 
zorg dragen voor hypofyse patiënten:
1. Cognitieve tekorten worden vaak gevonden bij de patiënten met hypofyse aandoeningen. Art-
sen zouden zich hiervan bewust moeten zijn, omdat dit duidelijke gevolgen kan hebben voor de 
patiënt. Gevolgen van dit verminderd cognitief functioneren kunnen betrekking hebben op het 
niet goed meer kunnen uitvoeren van het werk, moeilijkheden bij het plannen van de dag of het 
hebben van een verminderd zelfvertrouwen. Er lijken echter compensatiemogelijkheden aanwe-
zig te zijn waarmee de patiënt zich tot op zeker hoogte kan aanpassen. Dit is een bevinding die 
geruststelling kan bieden aan patiënten en het zou een nieuw uitgangspunt kunnen zijn bij de 
ontwikkeling van cognitieve revalidatieprogramma’s.
2. Artsen moeten zich bewust zijn van de veiligheidsprofielen van verschillende behandelvor-
men. Radiotherapie voor hypofyse aandoeningen wordt niet geassocieerd met grote negatieve 
effecten op het cognitief functioneren en dit argument mag daarom niet worden gebruikt om 
radiotherapie uit te stellen of te weigeren bij patiënten die hier profijt van kunnen hebben. Verder 
vonden we in onze cross-sectionele studies geen effecten van een medische behandeling voor 
acromegalie op het cognitieve functioneren.
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